0001564590-16-018296.txt : 20160506 0001564590-16-018296.hdr.sgml : 20160506 20160506163615 ACCESSION NUMBER: 0001564590-16-018296 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160506 DATE AS OF CHANGE: 20160506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL HEALTH REALTY INCOME TRUST CENTRAL INDEX KEY: 0000798783 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 236858580 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09321 FILM NUMBER: 161628610 BUSINESS ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH RD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: 610-265-0688 MAIL ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH ROAD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 10-Q 1 uht-10q_20160331.htm 10-Q uht-10q_20160331.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(MARK ONE)

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

OR

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                      

Commission file number 1-9321

 

UNIVERSAL HEALTH REALTY INCOME TRUST

(Exact name of registrant as specified in its charter)

 

 

MARYLAND

 

23-6858580

(State or other jurisdiction of

incorporation or organization)

 

(I. R. S. Employer

Identification No.)

 

 

 

UNIVERSAL CORPORATE CENTER

367 SOUTH GULPH ROAD

KING OF PRUSSIA, PENNSYLVANIA

 

19406

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code (610) 265-0688

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

o

Accelerated Filer

x

 

 

 

 

Non-accelerated filer

o

Smaller reporting company

o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x

Number of common shares of beneficial interest outstanding at April 30, 2016—13,328,083

 

 

 

 

 


UNIVERSAL HEALTH REALTY INCOME TRUST

INDEX

 

 

 

 

 

PAGE NO.

PART I. FINANCIAL INFORMATION

 

 

Item 1.

 

Financial Statements

 

 

 

 

Condensed Consolidated Statements of Income—Three  Months Ended March 31, 2016 and 2015

 

3

 

 

Condensed Consolidated Statements of Comprehensive Income—Three Months Ended March 31, 2016 and 2015

 

4

 

 

Condensed Consolidated Balance Sheets—March 31, 2016 and December 31, 2015

 

5

 

 

Condensed Consolidated Statements of Cash Flows—Three Months Ended March 31, 2016 and 2015

 

6

 

 

Notes to Condensed Consolidated Financial Statements

 

7 through 15

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

16 through 25

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

25

Item 4.

 

Controls and Procedures

 

25

PART II. Other Information

 

26

Item 6.

 

Exhibits

 

26

Signatures

 

27

EXHIBIT INDEX

 

28

This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2016. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

As disclosed in this Quarterly Report, including in Part I, Item 1.—Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions, a wholly-owned subsidiary of UHS (UHS of Delaware, Inc.) serves as our Advisor pursuant to the terms of an annually renewable Advisory Agreement dated December 24, 1986. Our officers are all employees of UHS through its wholly-owned subsidiary, UHS of Delaware, Inc. In addition, three of our hospital facilities are leased to subsidiaries of UHS and fourteen medical office buildings and two free-standing emergency departments, that are either wholly or jointly-owned by us, include tenants which are subsidiaries of UHS. Any reference to “UHS” or “UHS facilities” in this report is referring to Universal Health Services, Inc.’s subsidiaries, including UHS of Delaware, Inc.

In this Quarterly Report, the term “revenues” does not include the revenues of the unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%. We currently account for our share of the income/loss from these investments by the equity method (see Note 5 to the Condensed Consolidated Financial Statements included herein).

 

 

 

 


 

Part I. Financial Information

Item I. Financial Statements

Universal Health Realty Income Trust

Condensed Consolidated Statements of Income

For the Three Months Ended March 31, 2016 and 2015

(amounts in thousands, except per share amounts)

(unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2016

 

 

2015

 

Revenues:

 

 

 

 

 

 

 

 

Base rental - UHS facilities

 

$

4,081

 

 

$

3,906

 

Base rental - Non-related parties

 

 

8,815

 

 

 

8,869

 

Bonus rental - UHS facilities

 

 

1,246

 

 

 

1,218

 

Tenant reimbursements and other - Non-related parties

 

 

1,873

 

 

 

2,009

 

Tenant reimbursements and other - UHS facilities

 

 

211

 

 

 

200

 

 

 

 

16,226

 

 

 

16,202

 

Expenses:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

5,436

 

 

 

5,523

 

Advisory fees to UHS

 

 

767

 

 

 

666

 

Other operating expenses

 

 

4,400

 

 

 

4,722

 

Transaction costs

 

 

82

 

 

 

57

 

 

 

 

10,685

 

 

 

10,968

 

Income before equity in income of unconsolidated limited liability

   companies ("LLCs"), and interest expense

 

 

5,541

 

 

 

5,234

 

Equity in income of unconsolidated LLCs

 

 

1,059

 

 

 

592

 

Interest expense, net

 

 

(2,172

)

 

 

(2,130

)

Net income

 

$

4,428

 

 

$

3,696

 

Basic earnings per share

 

$

0.33

 

 

$

0.28

 

Diluted earnings per share

 

$

0.33

 

 

$

0.28

 

Weighted average number of shares outstanding – Basic

 

 

13,307

 

 

 

13,283

 

Weighted average number of share equivalents

 

 

7

 

 

 

11

 

Weighted average number of shares and equivalents

   outstanding – Diluted

 

 

13,314

 

 

 

13,294

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

3


 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Comprehensive Income

For the Three Months Ended March 31, 2016 and 2015

(dollar amounts in thousands)

(unaudited)

 

 

 

Three Months Ended

 

 

 

 

March 31,

 

 

 

 

2016

 

 

2015

 

 

Net Income

 

$

4,428

 

 

$

3,696

 

 

Other comprehensive income/(loss):

 

 

 

 

 

 

 

 

 

Unrealized derivative losses on interest rate caps

 

 

(2

)

 

 

(61

)

 

Amortization of interest rate cap fees

 

 

23

 

 

 

23

 

 

Total other comprehensive income/(loss):

 

 

21

 

 

 

(38

)

 

Total comprehensive income

 

$

4,449

 

 

$

3,658

 

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

4


 

Universal Health Realty Income Trust

Condensed Consolidated Balance Sheets

(dollar amounts in thousands)

(unaudited)

 

 

 

March 31,

 

 

December 31,

 

 

 

2016

 

 

2015

 

Assets:

 

 

 

 

 

 

 

 

Real Estate Investments:

 

 

 

 

 

 

 

 

Buildings and improvements

 

$

478,405

 

 

$

469,933

 

Accumulated depreciation

 

 

(125,287

)

 

 

(121,161

)

 

 

 

353,118

 

 

 

348,772

 

Land

 

 

44,053

 

 

 

41,724

 

Net Real Estate Investments

 

 

397,171

 

 

 

390,496

 

Investments in and advances to limited liability companies ("LLCs")

 

 

36,835

 

 

 

31,597

 

Other Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

4,316

 

 

 

3,894

 

Base and bonus rent receivable from UHS

 

 

2,350

 

 

 

2,116

 

Rent receivable - other

 

 

4,569

 

 

 

4,292

 

Intangible assets (net of accumulated amortization of $23.3 million and $25.1 million

   at March 31, 2016 and  December 31, 2015, respectively)

 

 

19,736

 

 

 

19,757

 

Deferred charges and other assets, net

 

 

6,130

 

 

 

6,351

 

Total Assets

 

$

471,107

 

 

$

458,503

 

Liabilities:

 

 

 

 

 

 

 

 

Line of credit borrowings

 

$

159,650

 

 

$

142,150

 

Mortgage and other notes payable, non-recourse to us, net

 

 

109,332

 

 

 

110,156

 

Accrued interest

 

 

538

 

 

 

504

 

Accrued expenses and other liabilities

 

 

6,107

 

 

 

6,807

 

Tenant reserves, escrows, deposits and prepaid rents

 

 

4,418

 

 

 

3,844

 

Total Liabilities

 

 

280,045

 

 

 

263,461

 

Equity:

 

 

 

 

 

 

 

 

Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized;

   none issued and outstanding

 

 

 

 

 

 

Common shares, $.01 par value; 95,000,000 shares authorized; issued

   and outstanding: 2016 - 13,328,033; 2015 -13,327,020

 

 

133

 

 

 

133

 

Capital in excess of par value

 

 

241,867

 

 

 

241,700

 

Cumulative net income

 

 

559,714

 

 

 

555,286

 

Cumulative dividends

 

 

(610,579

)

 

 

(601,983

)

Accumulated other comprehensive loss

 

 

(73

)

 

 

(94

)

Total Equity

 

 

191,062

 

 

 

195,042

 

Total Liabilities and Equity

 

$

471,107

 

 

$

458,503

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

5


 

Universal Health Realty Income Trust

Condensed Consolidated Statement of Cash Flows

(dollar amounts in thousands)

(unaudited)

 

 

 

Three months ended March 31,

 

 

 

2016

 

 

2015

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income

 

$

4,428

 

 

$

3,696

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

5,458

 

 

 

5,545

 

Amortization of debt premium

 

 

(56

)

 

 

(57

)

Stock-based compensation expense

 

 

111

 

 

 

101

 

Income in excess of cash distributions from LLCs

 

 

 

 

 

(64

)

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Rent receivable

 

 

(511

)

 

 

(194

)

Accrued expenses and other liabilities

 

 

(1,014

)

 

 

(658

)

Tenant reserves, escrows, deposits and prepaid rents

 

 

574

 

 

 

136

 

Accrued interest

 

 

34

 

 

 

(48

)

Other, net

 

 

70

 

 

 

(228

)

Net cash provided by operating activities

 

 

9,094

 

 

 

8,229

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Investments in LLCs

 

 

(5,386

)

 

 

(321

)

Repayments of advances made to LLC

 

 

209

 

 

 

 

Cash distributions in excess of income from LLCs

 

 

147

 

 

 

 

Cash distribution of refinancing proceeds from LLCs

 

 

 

 

 

1,045

 

Additions to real estate investments, net

 

 

(1,841

)

 

 

(2,168

)

Net cash paid for acquisition of properties

 

 

(9,910

)

 

 

(16,765

)

Cash paid to acquire minority interests in majority-owned LLCs

 

 

 

 

 

(2,250

)

Net cash used in investing activities

 

 

(16,781

)

 

 

(20,459

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Net borrowings on line of credit

 

 

17,500

 

 

 

26,250

 

Repayments of mortgages and other notes payable

 

 

(790

)

 

 

(5,743

)

Financing costs paid

 

 

(35

)

 

 

(913

)

Dividends paid

 

 

(8,596

)

 

 

(8,446

)

Issuance of shares of beneficial interest, net

 

 

30

 

 

 

1,172

 

Net cash provided by financing activities

 

 

8,109

 

 

 

12,320

 

Increase in cash and cash equivalents

 

 

422

 

 

 

90

 

Cash and cash equivalents, beginning of period

 

 

3,894

 

 

 

3,861

 

Cash and cash equivalents, end of period

 

$

4,316

 

 

$

3,951

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

 

Interest paid

 

$

2,072

 

 

$

2,115

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes to these condensed consolidated financial statements.

 

6


 

UNIVERSAL HEALTH REALTY INCOME TRUST

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2016

(unaudited)

 

(1) General

This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2016. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%.  As of March 31, 2016, we had investments in five jointly-owned LLCs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.

The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2015.

 

 

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each facility are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. These hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 25% of our consolidated revenues for each of the three months ended March 31, 2016 and 2015. Including 100% of the revenues generated at the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%, the leases on the UHS hospital facilities accounted for approximately 20% of the combined consolidated and unconsolidated revenue for each of the three months ended March 31, 2016 and 2015. In addition, we have sixteen medical office buildings (“MOBs”) or  free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us, include tenants which are subsidiaries of UHS.  

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month’s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.

 

7


 

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2016

 

 

15

 

(a)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2016

 

 

15

 

(b)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2016

 

 

15

 

(b)

 

(a)

UHS has three 5-year renewal options at existing lease rates (through 2031).

(b)

UHS has one 5-year renewal option at existing lease rates (through 2021) and two 5-year renewal options at fair market value lease rates (2022 through 2031).

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital and FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.  The existing lease terms for our three acute care hospitals operated by wholly-owned subsidiaries of UHS are scheduled to expire in December, 2016 and we can provide no assurance that these leases will be renewed at the existing lease rates.

During the first quarter of 2016, we committed to invest up to $21.1 million in the development and construction of the Henderson Medical Plaza, an MOB located on the campus of the Henderson Hospital Medical Center which is owned by a UHS subsidiary and also currently under construction. The hospital and MOB are both scheduled to be completed and opened during the fourth quarter of 2016.

Advisory Agreement: UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the “Advisory Agreement”) dated December 24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. In December of 2015, based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the Advisory agreement was renewed for 2016 pursuant to the same terms as the Advisory Agreement in place during 2015.

The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid during the first three months of 2016 or 2015 since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $767,000 and $666,000 for the three months ended March 31, 2016 and 2015, respectively, and were based upon average invested real estate assets of $438 million and $381 million for the three-month periods ended March 31, 2016 and 2015, respectively.

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of March 31, 2016 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

8


 

Share Ownership: As of March 31, 2016 and December 31, 2015, UHS owned 5.9% of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the leases on the hospital facilities leased to wholly-owned subsidiaries of UHS comprised approximately 25% of our consolidated revenues during each of the three month periods ended March 31, 2016 and 2015, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

 

 

(3) Dividends and Equity Issuance Program

Dividends:

We declared and paid dividends of $8.6 million, or $.645 per share, during the first quarter of 2016 and $8.4 million, or $.635 per share, during the first quarter of 2015.

Equity Issuance Program:

Subsequent to the first quarter of 2016, we recommenced our at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of approximately  $23.3 million to or through Merrill Lynch, Pierce, Fenner and Smith, Incorporated (“Merrill Lynch”), as sales agent and/or principal. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective in December, 2015.

There were no shares issued pursuant to the ATM program during the first three months of 2016. Since inception of this ATM program, we have issued 580,900 shares at an average price of $45.97 per share, which generated approximately $25.6 million of net proceeds (net of approximately $1.1 million, consisting of compensation of $667,000 to Merrill Lynch as well as $391,000 of other various fees and expenses). Included in cash received for the issuance of shares of beneficial interest, net, on the Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2015, was approximately $1.1 million received in connection with shares issued in late December, 2014.

 

 

(4) Acquisitions, Dispositions and New Construction

Three Months Ended March 31, 2016:

Acquisition:

In March, 2016, we purchased the Madison Professional Office Building located in Madison, Alabama for approximately $10.1 million. This multi-tenant property consists of approximately 30,100 rentable square feet and is fully occupied with an average remaining lease term of approximately 6.2 years at the time of acquisition.

 

The aggregate purchase price for this MOB was allocated to the assets acquired and liabilities assumed consisting of tangible property and identified intangible assets, based on the fair value estimated at acquisition as detailed in the table below. Substantially all of the intangible assets include the value of the in-place leases at the MOB at the time of acquisition which will be amortized over the average remaining lease term of approximately 6.2 years at the time of acquisition.

 

 

 

Land

$2,328

Buildings and improvements

6,523

Intangible assets

1,209

Deposit

(150)

 

 

Net cash paid

$9,910

 

 

9


 

New Construction:

During the first quarter of 2016, we committed to invest up to $21.1 million in the development and construction of the Henderson Medical Plaza, an MOB located on the campus of the Henderson Hospital Medical Center which is owned by a UHS subsidiary and also currently under construction. The hospital and MOB are both scheduled to be completed and opened during the fourth quarter of 2016.

Dispositions:  

There were no divestitures during the first three months of 2016.

Three Months Ended March 31, 2015:

Acquisitions:

In February, 2015, we purchased the Haas Medical Office Park, two single story buildings having an aggregate of approximately 16,000 rentable square feet, located in Ottumwa, Iowa, for approximately $4.1 million.

In January and February of 2015, we purchased from wholly-owned subsidiaries of UHS, the real property of two newly-constructed and recently opened FEDs located in Weslaco and Mission, Texas, for an aggregate acquisition cost of approximately $12.8 million. Each FED consists of approximately 13,600 square feet and is operated by wholly-owned subsidiaries of UHS. In connection with these acquisitions, ten-year lease agreements with six 5-year renewal terms were executed with UHS for each FED. In connection with the lease agreements, the lessee shall have the option to purchase the leased property upon the expiration of the fixed term and each five-year extended term at the fair market value at that time.

Dispositions:  

There were no divestitures during the first three months of 2015.

 

(5) Summarized Financial Information of Equity Affiliates

In accordance with the Financial Accounting Standards Board’s (“FASB”) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

At March 31, 2016, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. As of March 31, 2016, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that manage and hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties.

Effective February 1, 2016, we purchased an additional 10% ownership interest in the Arlington Medical Properties, LLC from the third-party minority member, subject to certain agreed upon terms and conditions. Including this additional ownership interest, we currently own 85% of this LLC which is accounted for on an unconsolidated basis pursuant to the equity method.

 

10


 

The following property table represents the five LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of March 31, 2016:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)

 

 

74

%

 

Mid Coast Hospital MOB

Arlington Medical Properties (b.)

 

 

85

%

 

Saint Mary’s Professional Office Building

Grayson Properties (c.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (d.)

 

 

95

%

 

Forney Medical Plaza II

 

(a.)

This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of March 31, 2016.

(b.)

We have funded $5.2 million in equity as of March 31, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date.  The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%.

(c.)

We have funded $2.8 million in equity as of March 31, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.6 million outstanding as of March 31, 2016.

(d.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.0 million has been funded as of March 31, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.4 million outstanding as of March 31, 2016.

 Below are the condensed combined statements of income (unaudited) for the LLCs accounted for under the equity method at March 31, 2016 and 2015.    

 

 

 

Three Months Ended

March 31,

 

 

 

 

2016

 

 

2015

 

 

 

 

(amounts in thousands)

Revenues

 

$

3,736

 

 

$

3,585

 

 

Operating expenses

 

 

1,353

 

 

 

1,337

 

 

Depreciation and amortization

 

 

613

 

 

 

580

 

 

Interest, net

 

 

657

 

 

 

619

 

 

Net income

 

$

1,113

 

 

$

1,049

 

 

Our share of net income (a.)

 

$

1,059

 

 

$

592

 

 

 

(a.)

Our share of net income for the three months ended March 31, 2016 includes interest income earned by us on an advance made to Arlington Medical Properties, LLC of approximately $296,000. There were no advances outstanding during the first three months of 2015, therefore there was no interest income earned by us for the three months ended March 31, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.

 

11


 

Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs in which we hold noncontrolling ownership interests and that were accounted for under the equity method as of March 31, 2016 and December 31, 2015:

 

 

 

March 31,

2016

 

 

December 31,

2015

 

 

 

(amounts in thousands)

 

Net property, including CIP

 

$

61,838

 

 

$

61,668

 

Other assets

 

 

5,415

 

 

 

5,264

 

Total assets

 

$

67,253

 

 

$

66,932

 

 

 

 

 

 

 

 

 

 

Liabilities

 

$

2,657

 

 

$

2,538

 

Mortgage notes payable, non-recourse to us

 

 

28,763

 

 

 

28,895

 

Advances payable to us

 

 

22,280

 

 

 

22,489

 

Equity

 

 

13,553

 

 

 

13,010

 

Total liabilities and equity

 

$

67,253

 

 

$

66,932

 

 

 

 

 

 

 

 

 

 

Our share of equity in  and advances to LLCs reflected as:

 

 

 

 

 

 

 

 

   Investments in LLCs (a.)

 

$

14,555

 

 

$

9,108

 

   Advances to LLCs

 

 

22,280

 

 

 

22,489

 

Subtotal-Investments in and advances to LLCs before

 

 

 

 

 

 

 

 

   amounts included in accrued expenses and other liabilities

 

 

36,835

 

 

 

31,597

 

   Amounts included in accrued expenses and other liabilities

 

 

(1,311

)

 

 

(1,105

)

Our share of equity in and advances to LLCs, net

 

$

35,524

 

 

$

30,492

 

 

 

(a.)

As mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.

 

As of March 31, 2016, and December 31, 2015, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

3/31/2016

 

 

12/31/2015

 

 

Maturity Date

FTX MOB Phase II

 

$

5,396

 

 

$

5,427

 

 

August, 2017

Grayson Properties

 

 

14,612

 

 

 

14,670

 

 

September, 2021

Brunswick Associates

 

 

8,755

 

 

 

8,798

 

 

December, 2024

 

 

$

28,763

 

 

$

28,895

 

 

 

 

(a.)

All mortgage loans, other than construction loans, require monthly principal payments through maturity and include a balloon principal payment upon maturity.

 

Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

 

 

(6) Recent Accounting Pronouncements

 

In March, 2016, the FASB issued ASU 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting, which requires an investor to initially apply the equity method of accounting from the date it qualified for that method.  The ASU eliminates the previous requirement to retroactively adjust the investment and record a cumulative catch up for the periods that the investment had been held, but did not qualify for the equity method of accounting.  The

12


 

amendments are effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted.  We are currently in the process of evaluating the impact of adoption of this ASU on our consolidated financial statements.

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASU 2016-02 supersedes the previous leases standard, Leases (Topic 840). The standard is effective on January 1, 2019, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of ASU 2016-02 will have on our financial position or results of operations.

 

In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs, an update to the accounting standard relating to the presentation of debt issuance costs. Under the new guidance, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability. In the event that there is not an associated debt liability recorded in the consolidated financial statements, the debt issuance costs will continue to be recorded on the consolidated balance sheet as an asset until the debt liability is recorded.  The new standard became effective for the Trust on January 1, 2016. The adoption of this guidance did not have a material impact on our consolidated financial position or results of operations as the update only related to changes in financial statement presentation.  

 

In February 2015, the FASB issued ASU No. 2015-02, Consolidation – Amendments to the Consolidation Analysis, which amends the current consolidation guidance affecting both the variable interest entity (“VIE”) and voting interest entity (“VOE”) consolidation models. The standard does not add or remove any of the characteristics in determining if an entity is a VIE or VOE, but rather enhances the way the Company assesses some of these characteristics. The new standard became effective for the Trust on January 1, 2016 and did not have a material impact on our consolidated financial position or results of operations as none of its existing consolidation conclusions were changed.

 

(7) Debt and Financial Instruments

Debt:

 

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $185 million revolving credit facility, the level of borrowings pursuant to non-course mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our at-the-market equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit facility borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On March 27, 2015, we entered into a new $185 million revolving credit agreement (“Credit Agreement”). The Credit Agreement, which will mature in March, 2019, replaced our previous revolving credit facility which was scheduled to mature in July, 2015. The Credit Agreement includes a $50 million sub limit for letters of credit and a $20 million sub limit for swingline/short-term loans. The Credit Agreement also provides a one-time option to extend the maturity date for an additional one year period, and an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement. Borrowings under the new facility are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the new facility are secured by first priority security interests in and liens on all equity interests in the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.50% to 2.00% or at the Base Rate plus an applicable margin ranging from 0.50% to 1.00%. The Credit Agreement defines “Base Rate” as the greatest of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%. A commitment fee of 0.20% to 0.40% (depending on our total leverage ratio) will be charged on the average unused portion of the revolving credit commitments. The margins over LIBOR, Base Rate and the commitment fee are based upon our ratio of debt to total capital. At March 31, 2016, the applicable margin over the LIBOR rate was 1.625%, the margin over the Base Rate was 0.625%, and the commitment fee was 0.25%.

13


 

At March 31, 2016, we had $159.7 million of outstanding borrowings and $3.0 million of letters of credit outstanding against our revolving credit agreement. We had $22.3 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2016. At December 31, 2015, we had $142.2 million of outstanding borrowings and $3.5 million of letters of credit outstanding against our revolving credit agreement. We had $39.3 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of December 31, 2015. There are no compensating balance requirements.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2016. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

 

March 31,

2016

 

Tangible net worth

 

$

125,000

 

 

$

171,326

 

Total leverage

 

< 60%

 

 

 

46.6

%

Secured leverage

 

< 30%

 

 

 

19.4

%

Unencumbered leverage

 

< 60%

 

 

 

46.2

%

Fixed charge coverage

 

> 1.50x

 

 

3.5x

 

 

As indicated on the following table, we have fourteen mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2016, with a combined outstanding balance of $109.5 million, excluding net debt premium of $242,000 and net of net financing fees of $376,000 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands)(a)

 

 

Interest

Rate

 

 

Maturity

Date

Summerlin Hospital Medical Office Building III

   floating rate mortgage loan (b.)

 

$

10,616

 

 

 

3.69

%

 

December, 2016

Peace Health fixed rate mortgage loan (b.)

 

 

20,671

 

 

 

5.64

%

 

April, 2017

Auburn Medical II floating rate mortgage loan (b.)

 

 

6,897

 

 

 

3.19

%

 

April, 2017

Medical Center of Western Connecticut fixed rate

   mortgage loan

 

 

4,631

 

 

 

6.00

%

 

June, 2017

Summerlin Hospital Medical Office Building II fixed

   rate mortgage loan

 

 

11,339

 

 

 

5.50

%

 

October, 2017

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

6,312

 

 

 

5.88

%

 

December, 2017

Centennial Hills Medical Office Building floating rate

   mortgage loan

 

 

10,266

 

 

 

3.69

%

 

January, 2018

Sparks Medical Building/Vista Medical Terrace

   floating rate mortgage loan

 

 

4,320

 

 

 

3.69

%

 

February, 2018

Rosenberg Children’s Medical Plaza fixed rate

   mortgage loan

 

 

8,275

 

 

 

4.85

%

 

May, 2018

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

 

2,793

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

6,384

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,453

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

5,179

 

 

 

3.62

%

 

January, 2023

Tuscan Professional Building fixed rate mortgage loan

 

 

5,330

 

 

 

5.56

%

 

June, 2025

Total

 

$

109,466

 

 

 

 

 

 

 

 

14


 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

(b.)

This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our revolving credit facility.

The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages have a combined fair value of approximately $112 million as of March 31, 2016. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

At December 31, 2015, we had fourteen mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these fourteen mortgages was $110.3 million (excluding net debt premium of $298,000 and net of net financing fees of $398,000), and had a combined fair value of approximately $112.4 million.

Financial Instruments:

During the third quarter of 2013, we entered into an interest rate cap on a total notional amount of $10 million whereby we paid a premium of $136,000. During the first quarter of 2014, we entered into two additional interest rate cap agreements on a total notional amount of $20 million whereby we paid premiums of $134,500. In exchange for the premium payments, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap. From inception through March 31, 2016, no payments have been made to us by the counterparties pursuant to the terms of these caps which expire in January, 2017.

 

(8) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.

 

 

15


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a real estate investment trust (“REIT”) that commenced operations in 1986. We invest in healthcare and human service related facilities currently including acute care hospitals, rehabilitation hospitals, sub-acute facilities, surgery centers, free-standing emergency departments, childcare centers and medical office buildings (“MOBs”). As of March 31, 2016, we have sixty-three real estate investments located in nineteen states consisting of:

 

·

six hospital facilities consisting of three acute care, one rehabilitation and two sub-acute;

 

·

three free-standing emergency departments (“FEDs”);

 

·

fifty medical office buildings, including five owned by unconsolidated limited liability companies (“LLCs”), and;

 

·

four pre-school and childcare centers.

Forward Looking Statements and Certain Risk Factors

You should carefully review all of the information contained in this Quarterly Report, and should particularly consider any risk factors that we set forth in this Quarterly Report and in other reports or documents that we file from time to time with the Securities and Exchange Commission (the “SEC”). In this Quarterly Report, we state our beliefs of future events and of our future financial performance. In some cases, you can identify those so-called “forward-looking statements” by words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “appears,” “projects” and similar expressions, as well as statements in future tense. You should be aware that those statements are only our predictions. Actual events or results may differ materially. In evaluating those statements, you should specifically consider various factors, including the risks outlined herein and in our Annual Report on Form 10-K for the year ended December 31, 2015 in Item 1A Risk Factors and in Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations—Forward Looking Statements. Those factors may cause our actual results to differ materially from any of our forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, such performance or results will be achieved. Forward-looking information is based on information available at the time and/or our good faith belief with respect to future events, and is subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Such factors include, among other things, the following:

 

·

a substantial portion of our revenues are dependent upon one operator, Universal Health Services, Inc. (“UHS”). We cannot assure you that subsidiaries of UHS will renew the leases on our three acute care hospitals (which are scheduled to expire in December, 2016) and two FEDs at existing lease rates or fair market value lease rates. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital facilities upon expiration of the lease terms, our future revenues and results of operations could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to these leases;

 

·

in certain of our markets, the general real estate market has been unfavorably impacted by increased competition/capacity and decreases in occupancy and rental rates which may adversely impact our operating results and the underlying value of our properties;

 

·

a number of legislative initiatives have recently been passed into law that may result in major changes in the health care delivery system on a national or state level to the operators of our facilities, including UHS. No assurances can be given that the implementation of these new laws will not have a material adverse effect on the business, financial condition or results of operations of our operators;

 

·

a subsidiary of UHS is our Advisor and our officers are all employees of a wholly-owned subsidiary of UHS, which may create the potential for conflicts of interest;

 

·

lost revenues resulting from the exercise of purchase options, lease expirations and renewals, loan repayments and other restructuring;

 

·

our ability to continue to obtain capital on acceptable terms, including borrowed funds, to fund future growth of our business;

 

·

the outcome of known and unknown litigation, government investigations, and liabilities and other claims asserted against us or the operators of our facilities;

16


 

 

·

failure of the operators of our hospital facilities to comply with governmental regulations related to the Medicare and Medicaid licensing and certification requirements could have a material adverse impact on our future revenues and the underlying value of the property; 

 

·

the potential unfavorable impact on our business of deterioration in national, regional and local economic and business conditions, including a worsening of credit and/or capital market conditions, which may adversely affect, our ability to obtain capital which may be required to fund the future growth of our business and refinance existing debt with near term maturities;

 

·

a deterioration in general economic conditions which could result in increases in the number of people unemployed and/or insured and likely increase the number of individuals without health insurance; as a result, the operators of our facilities may experience decreases in patient volumes which could result in decreased occupancy rates at our medical office buildings;

 

·

a worsening of the economic and employment conditions in the United States could materially affect the business of our operators, including UHS, which may unfavorably impact our future bonus rentals (on the UHS hospital facilities) and may potentially have a negative impact on the future lease renewal terms and the underlying value of the hospital properties;

 

·

real estate market factors, including without limitation, the supply and demand of office space and market rental rates, changes in interest rates as well as an increase in the development of medical office condominiums in certain markets;

 

·

government regulations, including changes in the reimbursement levels under the Medicare and Medicaid program resulting from, among other things, the various health care reform initiatives being implemented;

 

·

there have been several attempts in Congress to repeal or modify various provisions of the Patient Protection and Affordable Care Act (the “PPACA”). We cannot predict whether or not any of these proposed changes to the PPACA will become law and therefore can provide no assurance that changes to the PPACA, as currently implemented, will not have a material adverse effect on the future operating results of the tenants/operators of our properties and, thus, our business;

 

·

the issues facing the health care industry that affect the operators of our facilities, including UHS, such as: changes in, or the ability to comply with, existing laws and government regulations; unfavorable changes in the levels and terms of reimbursement by third party payors or government programs, including Medicare (including, but not limited to, the potential unfavorable impact of future reductions to Medicare reimbursements resulting from the Budget Control Act of 2011, as discussed below) and Medicaid (most states have reported significant budget deficits that have, in the past, resulted in the reduction of Medicaid funding to the operators of our facilities, including UHS); demographic changes; the ability to enter into managed care provider agreements on acceptable terms; an increase in uninsured and self-pay patients which unfavorably impacts the collectability of patient accounts; decreasing in-patient admission trends; technological and pharmaceutical improvements that may increase the cost of providing, or reduce the demand for, health care, and; the ability to attract and retain qualified medical personnel, including physicians;

 

·

in August, 2011, the Budget Control Act of 2011 (the “2011 Act”) was enacted into law. The 2011 Act imposed annual spending limits for most federal agencies and programs aimed at reducing budget deficits by $917 billion between 2012 and 2021, according to a report released by the Congressional Budget Office. The 2011 Act provides for new spending on program integrity initiatives intended to reduce fraud and abuse under the Medicare program. Among its other provisions, the law established a bipartisan Congressional committee, known as the Joint Select Committee on Deficit Reduction (the “Joint Committee”), which was tasked with making recommendations aimed at reducing future federal budget deficits by an additional $1.5 trillion over 10 years. The Joint Committee was unable to reach an agreement by the November 23, 2011 deadline and, as a result, across-the-board cuts to discretionary, national defense and Medicare spending were implemented on March 1, 2013 resulting in Medicare payment reductions of up to 2% per fiscal year with a uniform percentage reduction across all Medicare programs. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, continued the 2% reductions to Medicare reimbursement imposed under the 2011 Act.  We cannot predict whether Congress will restructure the implemented Medicare payment reductions or what federal other deficit reduction initiatives may be proposed by Congress going forward. We also cannot predict the effect these enactments will have on operators (including UHS), and, thus, our business;

 

·

in March, 2010, the Health Care and Education Reconciliation Act of 2010 and the Patient Protection and Affordable Care Act were enacted into law and created significant changes to health insurance coverage for U.S. citizens as well as material revisions to the federal Medicare and state Medicaid programs. The two combined primary goals of these acts are to provide for increased access to coverage for healthcare and to reduce healthcare-related expenses. Medicare, Medicaid and other health care industry changes are scheduled to be implemented at various times during this decade. We cannot predict the effect, if any, these enactments will have on operators (including UHS) and, thus, our business;

17


 

 

·

competition for our operators from other REITs; 

 

·

the operators of our facilities face competition from other health care providers, including physician owned facilities and other competing facilities, including certain facilities operated by UHS but the real property of which is not owned by us. Such competition is experienced in markets including, but not limited to, McAllen, Texas, the site of our McAllen Medical Center, a 430-bed acute care hospital, and Riverside County, California, the site of our Southwest Healthcare System-Inland Valley Campus, a 132-bed acute care hospital;

 

·

changes in, or inadvertent violations of, tax laws and regulations and other factors than can affect REITs and our status as a REIT;

 

·

should we be unable to comply with the strict income distribution requirements applicable to REITs, utilizing only cash generated by operating activities, we would be required to generate cash from other sources which could adversely affect our financial condition;

 

·

our ownership interests in five LLCs/LPs in which we hold non-controlling equity interests. In addition, pursuant to the operating and/or partnership agreements of the five entities in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member;

 

·

fluctuations in the value of our common stock, and;

 

·

other factors referenced herein or in our other filings with the Securities and Exchange Commission.

Given these uncertainties, risks and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Our actual results and financial condition, including the operating results of our lessees and the facilities leased to subsidiaries of UHS, could differ materially from those expressed in, or implied by, the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. We assume no obligation to publicly update any forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except as may be required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.  

We consider our critical accounting policies to be those that require us to make significant judgments and estimates when we prepare our financial statements, including the following:

Revenue Recognition:    Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals), bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.

The minimum rent for all hospital facilities is fixed over the initial term or renewal term of the respective leases. Rental income recorded by our properties, including our consolidated and unconsolidated MOBs, relating to leases in excess of one year in length, is recognized using the straight-line method under which contractual rents are recognized evenly over the lease term regardless of when payments are due. The amount of rental revenue resulting from straight-line rent adjustments is dependent on many factors including the nature and amount of any rental concessions granted to new tenants, stipulated rent increases under existing leases, as well as the acquisitions and sales of properties that have existing in-place leases with terms in excess of one year. As a result, the straight-line adjustments to rental revenue may vary from period-to-period. Bonus rents are recognized when earned based upon increases in each facility’s net revenue in excess of stipulated amounts. Bonus rentals are determined and paid each quarter based upon a computation

18


 

that compares the respective facility’s current quarter’s net revenue to the corresponding quarter in the base year. Tenant reimbursements for operating expenses are accrued as revenue in the same period the related expenses are incurred.

Real Estate Investments:    On the date of acquisition, the purchase price of a property is allocated to the property’s land, buildings and intangible assets based upon our estimates of their fair values. Depreciation is computed using the straight-line method over the useful lives of the buildings and capital improvements. The value of intangible assets is amortized over the remaining lease term.

Asset Impairment:    Real estate investments and related intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the property might not be recoverable. A property to be held and used is considered impaired only if management’s estimate of the aggregate future cash flows, less estimated capital expenditures, to be generated by the property, undiscounted and without interest charges, are less than the carrying value of the property. This estimate takes into consideration factors such as expected future operating income, trends and prospects, as well as the effects of demand, competition, local market conditions and other factors.

The determination of undiscounted cash flows requires significant estimates by management, including the expected course of action at the balance sheet date that would lead to such cash flows. Subsequent changes in estimated undiscounted cash flows arising from changes in anticipated action to be taken with respect to the property could impact the determination of whether an impairment exists and whether the effects could materially impact our net income. To the extent estimated undiscounted cash flows are less than the carrying value of the property, the loss will be measured as the excess of the carrying amount of the property over the fair value of the property.

Assessment of the recoverability by us of certain lease related costs must be made when we have reason to believe that a tenant might not be able to perform under the terms of the lease as originally expected. This requires us to make estimates as to the recoverability of such costs. If we determine that the intangible assets are not recoverable from future cash flows, the excess of carrying value of the intangible asset over its estimated fair value is charged to income.

An other than temporary impairment of an investment in an LLC is recognized when the carrying value of the investment is not considered recoverable based on evaluation of the severity and duration of the decline in value, including projected declines in cash flow. To the extent impairment has occurred, the excess carrying value of the asset over its estimated fair value is charged to income.

Federal Income Taxes:    No provision has been made for federal income tax purposes since we qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986, and intend to continue to remain so qualified. As such, we are exempt from federal income taxes and we are required to distribute at least 90% of our real estate investment taxable income to our shareholders.

We are subject to a federal excise tax computed on a calendar year basis. The excise tax equals 4% of the amount by which 85% of our ordinary income plus 95% of any capital gain income for the calendar year exceeds cash distributions during the calendar year, as defined. No provision for excise tax has been reflected in the financial statements as no tax is expected to be due.

Earnings and profits, which determine the taxability of dividends to shareholders, will differ from net income reported for financial reporting purposes due to the differences for federal tax purposes in the cost basis of assets and in the estimated useful lives used to compute depreciation and the recording of provision for investment losses.

Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions—UHS is our principal tenant and through UHS of Delaware, Inc., a wholly owned subsidiary of UHS, serves as our advisor (the “Advisor”) under an Advisory Agreement dated December 24, 1986 between the Advisor and us (the “Advisory Agreement”). Our officers are all employees of UHS (through UHS of Delaware, Inc.) and although as of March 31, 2016 we had no salaried employees, our officers do receive stock-based compensation from time-to-time.

Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. In December of 2015, based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the Advisory Agreement was renewed for 2016 pursuant to the same terms as the Advisory Agreement in place during 2015.

19


 

The combined revenues generated from the leases on the UHS hospital facilities comprised approximately 25% of our consolidated revenues for each of the three months ended March 31, 2016 and 2015. Including 100% of the revenues generated at the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%, the leases on the UHS hospital facilities accounted for approximately 20% of the combined consolidated and unconsolidated revenue for each of the three months ended March 31, 2016 and 2015. In addition, sixteen MOBs and FEDs, that are either wholly or jointly-owned by UHT, include tenants which are subsidiaries of UHS.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month’s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.  The leases to the hospital facilities of UHS are guaranteed by UHS and cross-defaulted with one another.

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital and FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.  The existing lease terms for our three acute care hospitals operated by wholly-owned subsidiaries of UHS are scheduled to expire in December, 2016 and we can provide no assurance that these leases will be renewed at the existing lease rates.

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of March 31, 2016 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

For additional disclosure related to our relationship with UHS, please refer to Note 2 to the condensed consolidated financial statements, Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions.

Results of Operations

For the three months ended March 31, 2016, net income was $4.4 million as compared to $3.7 million during the comparable prior year quarter. The $732,000 increase in net income during the first quarter of 2016, as compared to the comparable prior year quarter, was attributable to:

 

·

an increase attributable to the property exchange transaction completed during the second quarter of 2015;

 

·

an increase resulting from lower cost of borrowings related to a previously outstanding third-party mortgage loan of an unconsolidated LLC which was repaid during the fourth quarter of 2015 utilizing funds borrowed under our revolving credit facility which were advanced to the LLC in the form of a member loan, and;

 

·

increased net income generated at various properties.

Included in our other operating expenses are expenses related to the consolidated medical office buildings, which totaled $3.9 million and $4.3 million for the three-month periods ended March 31, 2016 and 2015, respectively. A large portion of the expenses associated with our consolidated medical office buildings is passed on directly to the tenants either directly as tenant reimbursements of common area maintenance expenses or included in base rental amounts. Tenant reimbursements for operating expenses are accrued as revenue in the same period the related expenses are incurred and are included as tenant reimbursement revenue in our condensed consolidated statements of income.

Funds from operations (“FFO”) is a widely recognized measure of performance for Real Estate Investment Trusts (“REITs”). We believe that FFO and FFO per diluted share, and adjusted funds from operations (“AFFO”) and AFFO per diluted share, which are

20


 

non-GAAP financial measures (“GAAP” is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. We compute FFO, as reflected below, in accordance with standards established by the National Association of Real Estate Investment Trusts (“NAREIT”), which may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, or that interpret the NAREIT definition differently than we interpret the definition. AFFO was also computed for the three-month periods ended March 31, 2016 and 2015, as reflected below, since we believe it is helpful to our investors since it adjusts for the effect of the transaction costs related to acquisitions. FFO/AFFO do not represent cash generated from operating activities in accordance with GAAP and should not be considered to be an alternative to net income determined in accordance with GAAP. In addition, FFO/AFFO should not be used as: (i) an indication of our financial performance determined in accordance with GAAP; (ii) an alternative to cash flow from operating activities determined in accordance with GAAP; (iii) a measure of our liquidity, or; (iv) an indicator of funds available for our cash needs, including our ability to make cash distributions to shareholders.

Below is a reconciliation of our reported net income to FFO and AFFO for the three-month periods ended March 31, 2016 and 2015 (in thousands):

 

 

 

Three Months Ended

March 31,

 

 

 

2016

 

 

2015

 

Net income

 

$

4,428

 

 

$

3,696

 

Depreciation and amortization expense on consolidated

   investments

 

 

5,333

 

 

 

5,410

 

Depreciation and amortization expense on unconsolidated

   affiliates

 

 

450

 

 

 

410

 

Funds From Operations

 

 

10,211

 

 

 

9,516

 

Transaction costs

 

 

82

 

 

 

57

 

Adjusted Funds From Operations

 

$

10,293

 

 

$

9,573

 

 

Our FFO and AFFO increased by $695,000 and $720,000, respectively, during the three-month period ended March 31, 2016, as compared to the comparable period of 2015.  The increases in FFO and AFFO during the first quarter of 2016, as compared to the first quarter of 2015, were primarily due to the increase in net income, as discussed above.

Liquidity and Capital Resources

Net cash provided by operating activities

Net cash provided by operating activities was $9.1 million and $8.2 million during the three-month periods ended March 31, 2016 and 2015, respectively. The $865,000 net increase was attributable to:

 

·

a favorable change of $720,000 due to an increase in net income plus/minus the adjustments to reconcile net income to net cash provided by operating activities (depreciation and amortization, amortization of debt net premium, stock-based compensation expense and income in excess of cash distributions from LLCs), as discussed above in Results of Operations, and;

 

·

other combined net favorable changes of $145,000.

Net cash used in investing activities

Net cash used in investing activities was $16.8 million during the three months ended March 31, 2016 as compared to $20.5 million during the three months ended March 31, 2015.

During the three-month period ended March 31, 2016, we funded: (i) $5.4 million in equity investments in various unconsolidated LLCs, including $4.8 million to purchase an additional 10% equity interest in the Arlington Medical Plaza LLC, as discussed above; (ii) $1.8 million in capital additions to real estate investments primarily related to tenant improvements at various MOBs, and; (iii) $9.9 million to acquire the real estate assets of a medical office building, as discussed above.  In addition, during the three-month period ended March 31, 2016, we received: (i) $209,000 as an installment repayment of an outstanding member loan advanced to an unconsolidated LLC, and; (ii) $147,000 of cash distributions in excess of income received from our unconsolidated LLCs.

During the three-month period ended March 31, 2015, we funded: (i) $321,000 in equity investments in various unconsolidated LLCs; (ii) $2.2 million in capital additions to real estate investments primarily related to tenant improvements at various MOBs; (iii) $16.8 million to acquire the real estate assets of a medical office building and two free-standing emergency departments, and; (iv) $2.3

21


 

million payment of a note payable related to the purchase of third-party minority ownership interests in six majority-owned LLCs during the third quarter of 2014. In addition, during the three-month period ended March 31, 2015, we received $1.0 million of cash proceeds in connection with the refinancing of third-party debt by an unconsolidated LLC.

Net cash provided financing activities

Net cash provided by financing activities was $8.1 million during the three months ended March 31, 2016, as compared to $12.3 million during the three months ended March 31, 2015.

During the three-month period ended March 31, 2016, we received $17.5 million of additional net borrowings on our revolving line of credit. Additionally, during the three months ended March 31, 2016, we paid: (i) $790,000 on mortgages and other notes payable that are non-recourse to us; (ii) $35,000 of financing costs related to the revolving credit facility, and; (iii) $8.6 million of dividends.

During the three-month period ended March 31, 2015, we: (i) received $26.3 million of additional net borrowings on our revolving line of credit, and; (ii) received $1.2 million of net cash from the issuance of shares of beneficial interest (primarily relating to shares issued pursuant to our at-the-market equity issuance program in late December, 2014). Additionally, during the three months ended March 31, 2015, we paid: (i) $5.7 million on mortgages and other notes payable that are non-recourse to us, (including the pay-off of the $4.9 million third-party mortgage on the Spring Valley Medical Office Building utilizing funds borrowed under our revolving credit facility); (ii) $913,000 of financing costs paid on the new revolving credit facility, and; (iii) $8.4 million of dividends.

Subsequent to the first quarter of 2016, we recommenced our at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of approximately  $23.3 million to or through Merrill Lynch, Pierce, Fenner and Smith, Incorporated (“Merrill Lynch”), as sales agent and/or principal. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective in December, 2015.

There were no shares issued pursuant to the ATM program during the first three months of 2016. Since inception of this ATM program, we have issued 580,900 shares at an average price of $45.97 per share, which generated approximately $25.6 million of net proceeds (net of approximately $1.1 million, consisting of compensation of $667,000 to Merrill Lynch as well as $391,000 of other various fees and expenses). Included in cash received for the issuance of shares of beneficial interest, net, on the Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2015, was approximately $1.1 million received in connection with shares issued in late December, 2014.  

Additional cash flow and dividends paid information for the three-month periods ended March 31, 2016 and 2015:

As indicated on our condensed consolidated statement of cash flows, we generated net cash provided by operating activities of $9.1 million and $8.2 million during the three-month periods ended March 31, 2016 and 2015, respectively. As also indicated on our statement of cash flows, noncash expenses including depreciation and amortization, amortization of debt premium and stock-based compensation, as well as the income in excess of cash distributions from LLCs, are the primary differences between our net income and net cash provided by operating activities during each period.  In addition, as reflected in the cash flows from investing activities section, we received $147,000 during the three months ended March 31, 2016 of cash distributions in excess of income from various unconsolidated LLCs which represents our share of the net cash flow distributions from these entities. The cash distributions in excess of income represent operating cash flows net of capital expenditures and debt repayments made by the LLCs.

We generated $9.2 million and $8.2 million of net cash during the three months ended March 31, 2016 and 2015, respectively, related to the operating activities of our properties recorded on a consolidated and an unconsolidated basis. We paid dividends of $8.6 million and $8.4 million during the three months ended March 31, 2016 and 2015, respectively. During the first three months of 2016, the $9.2 million of net cash generated related to the operating activities of our properties was approximately $645,000 greater than the $8.6 million of dividends paid during the first quarter of 2016. During the first three months of 2015, the $8.2 million of net cash generated related to operating activities of our properties was approximately $217,000 less than the $8.4 million of dividends paid during the first quarter of 2015.

As indicated in the cash flows from investing activities and cash flows from financing activities sections of the statements of cash flows, there were various other sources and uses of cash during the three months ended March 31, 2016 and 2015. From time to time, various other sources and uses of cash may include items such as investments and advances made to/from LLCs, additions to real estate investments, acquisition/divestiture of properties, net borrowings/repayments of debt, and proceeds generated from the issuance of equity. Therefore, in any given period, the funding source for our dividend payments is not wholly dependent on the operating cash flow generated by our properties. Rather, our dividends as well as our capital reinvestments into our existing properties, acquisitions of real property and other investments are funded based upon the aggregate net cash inflows or outflows from all sources and uses of cash from the properties we own either in whole or through LLCs, as outlined above.

22


 

In determining and monitoring our dividend level on a quarterly basis, our management and Board of Trustees consider many factors in determining the amount of dividends to be paid each period. These considerations primarily include: (i) the minimum required amount of dividends to be paid in order to maintain our REIT status; (ii) the current and projected operating results of our properties, including those owned in LLCs, and; (iii) our future capital commitments and debt repayments, including those of our LLCs. Based upon the information discussed above, as well as consideration of projections and forecasts of our future operating cash flows, management and the Board of Trustees have determined that our operating cash flows have been sufficient to fund our dividend payments. Future dividend levels will be determined based upon the factors outlined above with consideration given to our projected future results of operations.

We expect to finance all capital expenditures and acquisitions and pay dividends utilizing internally generated and additional funds. Additional funds may be obtained through: (i) borrowings under our existing $185 million revolving credit facility agreement (which has $22.3 million of available borrowing capacity, net of outstanding borrowings and letters of credit, as of March 31, 2016); (ii) the issuance of equity pursuant to an at-the-market equity issuance program; (iii) borrowings under or refinancing of existing third-party debt pursuant to mortgage and construction loan agreements entered into by our LLCs, and/or; (iv) the issuance of other long-term debt.

We believe that our operating cash flows, cash and cash equivalents, available borrowing capacity under our revolving credit facility and access to the capital markets provide us with sufficient capital resources to fund our operating, investing and financing requirements for the next twelve months, including providing sufficient capital to allow us to make distributions necessary to enable us to continue to qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986. In the event we need to access the capital markets or other sources of financing, there can be no assurance that we will be able to obtain financing on acceptable terms or within an acceptable time. Our inability to obtain financing on terms acceptable to us could have a material unfavorable impact on our results of operations, financial condition and liquidity.

Credit facilities and mortgage debt

 

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $185 million revolving credit facility, the level of borrowings pursuant to non-course mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our at-the-market equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit facility borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On March 27, 2015, we entered into a new $185 million revolving credit agreement (“Credit Agreement”). The Credit Agreement, which will mature in March, 2019, replaced our previous revolving credit facility which was scheduled to mature in July, 2015. The Credit Agreement includes a $50 million sub limit for letters of credit and a $20 million sub limit for swingline/short-term loans. The Credit Agreement also provides a one-time option to extend the maturity date for an additional one year period, and an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement. Borrowings under the new facility are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the new facility are secured by first priority security interests in and liens on all equity interests in the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.50% to 2.00% or at the Base Rate plus an applicable margin ranging from 0.50% to 1.00%. The Credit Agreement defines “Base Rate” as the greatest of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%. A commitment fee of 0.20% to 0.40% (depending on our total leverage ratio) will be charged on the average unused portion of the revolving credit commitments. The margins over LIBOR, Base Rate and the commitment fee are based upon our ratio of debt to total capital. At March 31, 2016, the applicable margin over the LIBOR rate was 1.625%, the margin over the Base Rate was 0.625%, and the commitment fee was 0.25%.

At March 31, 2016, we had $159.7 million of outstanding borrowings and $3.0 million of letters of credit outstanding against our revolving credit agreement. We had $22.3 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2016. At December 31, 2015, we had $142.2 million of outstanding borrowings and $3.5 million of letters of credit outstanding against our revolving credit agreement. We had $39.3 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of December 31, 2015.  There are no compensating balance requirements.

23


 

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2016. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands): 

 

 

Covenant

 

 

March 31,

2016

 

Tangible net worth

 

$

125,000

 

 

$

171,326

 

Total leverage

 

< 60%

 

 

 

46.6

%

Secured leverage

 

< 30%

 

 

 

19.4

%

Unencumbered leverage

 

< 60%

 

 

 

46.2

%

Fixed charge coverage

 

> 1.50x

 

 

3.5x

 

 

As indicated on the following table, we have fourteen mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2016, with a combined outstanding balance of $109.5 million, excluding net debt premium of $242,000 and net of net financing fees of $376,000 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands)(a)

 

 

Interest

Rate

 

 

Maturity

Date

Summerlin Hospital Medical Office Building III

   floating rate mortgage loan (b.)

 

$

10,616

 

 

 

3.69

%

 

December, 2016

Peace Health fixed rate mortgage loan (b.)

 

 

20,671

 

 

 

5.64

%

 

April, 2017

Auburn Medical II floating rate mortgage loan (b.)

 

 

6,897

 

 

 

3.19

%

 

April, 2017

Medical Center of Western Connecticut fixed rate

   mortgage loan

 

 

4,631

 

 

 

6.00

%

 

June, 2017

Summerlin Hospital Medical Office Building II fixed

   rate mortgage loan

 

 

11,339

 

 

 

5.50

%

 

October, 2017

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

6,312

 

 

 

5.88

%

 

December, 2017

Centennial Hills Medical Office Building floating rate

   mortgage loan

 

 

10,266

 

 

 

3.69

%

 

January, 2018

Sparks Medical Building/Vista Medical Terrace

   floating rate mortgage loan

 

 

4,320

 

 

 

3.69

%

 

February, 2018

Rosenberg Children’s Medical Plaza fixed rate

   mortgage loan

 

 

8,275

 

 

 

4.85

%

 

May, 2018

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

 

2,793

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

6,384

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,453

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

5,179

 

 

 

3.62

%

 

January, 2023

Tuscan Professional Building fixed rate mortgage loan

 

 

5,330

 

 

 

5.56

%

 

June, 2025

Total

 

$

109,466

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.

(b.)

This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our revolving credit facility.

Off Balance Sheet Arrangements

As of March 31, 2016, we are party to certain off balance sheet arrangements consisting of standby letters of credit and equity and debt financing commitments. Our outstanding letters of credit at March 31, 2016 totaled $3.0 million consisting of: (i) $1.9 million

24


 

related to Centennial Hills Medical Properties; (ii) $450,000 related to FTX MOB Phase II, LP, and; (iii) $650,000 related to Banburry Medical Properties.

Acquisition and Divestiture Activity

Please see Note 4 to the condensed consolidated financial statements for completed transactions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Reference is made to Item 7A in our Annual Report on Form 10-K for the year ended December 31, 2015. There have been no material changes in the quantitative and qualitative disclosures during the first three months of 2016.

Item 4. Controls and Procedures

As of March 31, 2016, under the supervision and with the participation of our management, including the Trust’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), we performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “1934 Act”).

Based on this evaluation, the CEO and CFO have concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the 1934 Act and the SEC rules thereunder.

There have been no changes in our internal control over financial reporting or in other factors during the first three months of 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

25


 

PART II. OTHER INFORMATION

UNIVERSAL HEALTH REALTY INCOME TRUST

Item 1A. Risk Factors

Our Annual Report on Form 10-K for the year ended December 31, 2015 includes a listing of risk factors to be considered by investors in our securities. There have been no material changes in our risk factors from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2015.

Item 6. Exhibits

(a.) Exhibits:

 

  31.1

 

Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  31.2

 

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  32.1

 

Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

  32.2

 

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

 

 

26


 

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: May 6, 2016

 

UNIVERSAL HEALTH REALTY INCOME TRUST

(Registrant)

 

 

 

 

 

/s/ Alan B. Miller 

 

 

Alan B. Miller,

 

 

Chairman of the Board,

President and Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 

/s/ Charles F. Boyle 

 

 

Charles F. Boyle, Vice President and Chief Financial Officer

(Principal Financial Officer)

 

27


 

EXHIBIT INDEX

 

Exhibit

No.

 

Description

 

 

 

  31.1

 

Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  31.2

 

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  32.1

 

Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

  32.2

 

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

 

 

28

EX-31.1 2 uht-ex311_8.htm EX-31.1 uht-ex311_8.htm

 

Exhibit 31.1

CERTIFICATION—Chief Executive Officer

I, Alan B. Miller, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 6, 2016

 

/s/ Alan B. Miller 

President and Chief Executive Officer

 

 

EX-31.2 3 uht-ex312_6.htm EX-31.2 uht-ex312_6.htm

 

Exhibit 31.2

CERTIFICATION—Chief Financial Officer

I, Charles F. Boyle, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 6, 2016

 

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

 

 

EX-32.1 4 uht-ex321_7.htm EX-32.1 uht-ex321_7.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan B. Miller, President and Chief Executive Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

 

/s/ Alan B. Miller

President and Chief Executive Officer

May 6, 2016

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-32.2 5 uht-ex322_9.htm EX-32.2 uht-ex322_9.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles F. Boyle, Vice President and Chief Financial Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

 

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

May 6, 2016

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-101.INS 6 uht-20160331.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure uht:Property uht:Time uht:RenewalOption utr:sqft uht:Building uht:Option uht:MortgageLoan uht:Derivative uht:Segment 0000798783 2016-01-01 2016-03-31 0000798783 2016-04-30 0000798783 2015-01-01 2015-03-31 0000798783 2016-03-31 0000798783 2015-12-31 0000798783 2014-12-31 0000798783 2015-03-31 0000798783 us-gaap:MinimumMember uht:UnconsolidatedLimitedLiabilitiesMember 2016-03-31 0000798783 us-gaap:MaximumMember uht:UnconsolidatedLimitedLiabilitiesMember 2016-03-31 0000798783 uht:MedicalOfficeBuildingsMember us-gaap:LimitedLiabilityCompanyMember 2016-03-31 0000798783 uht:UniversalHealthServicesIncMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0000798783 uht:UniversalHealthServicesIncMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0000798783 uht:UniversalHealthServicesIncMember 2016-03-31 0000798783 uht:UniversalHealthServicesIncMember 2016-01-01 2016-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2015-01-01 2015-03-31 0000798783 uht:CombinedMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-03-31 0000798783 uht:CombinedMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2015-01-01 2015-03-31 0000798783 uht:McAllenMedicalCenterMember 2016-03-31 0000798783 uht:WellingtonRegionalMedicalCenterMember 2016-03-31 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember 2016-03-31 0000798783 uht:McAllenMedicalCenterMember 2016-01-01 2016-03-31 0000798783 uht:WellingtonRegionalMedicalCenterMember 2016-01-01 2016-03-31 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember 2016-01-01 2016-03-31 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-03-31 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-03-31 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember us-gaap:MinimumMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-03-31 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember us-gaap:MaximumMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2016-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember us-gaap:MinimumMember 2016-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2016-01-01 2016-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2015-01-01 2015-03-31 0000798783 uht:UniversalHealthServicesIncMember 2015-12-31 0000798783 uht:AtMarketATMProgramsMember 2016-01-01 2016-03-31 0000798783 uht:AtMarketATMProgramsMember 2013-10-01 2016-03-31 0000798783 uht:AtMarketATMProgramsMember us-gaap:OtherExpenseMember 2013-10-01 2016-03-31 0000798783 uht:AtMarketATMProgramsMember 2015-01-01 2015-03-31 0000798783 uht:MadisonProfessionalOfficeBuildingMember 2016-03-31 0000798783 uht:MadisonProfessionalOfficeBuildingMember 2016-03-01 2016-03-31 0000798783 uht:MedicalOfficeBuildingsMember 2016-01-01 2016-03-31 0000798783 uht:TwoThousandSixteenAcquisitionsMember 2016-03-31 0000798783 2015-02-01 2015-02-28 0000798783 2015-02-28 0000798783 uht:FreestandingEmergencyDepartmentsMember 2015-01-01 2015-02-28 0000798783 uht:FreestandingEmergencyDepartmentsMember 2015-02-28 0000798783 uht:FreestandingEmergencyDepartmentsMember uht:UniversalHealthServicesIncMember 2015-02-28 0000798783 uht:FreestandingEmergencyDepartmentsMember uht:UniversalHealthServicesIncMember 2015-01-01 2015-02-28 0000798783 us-gaap:MinimumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2016-03-31 0000798783 us-gaap:MaximumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2016-03-31 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember uht:MedicalOfficeBuildingsMember 2016-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2016-03-31 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-03-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2016-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-03-31 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-03-31 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2016-03-31 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-03-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-03-31 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-03-31 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-03-31 0000798783 uht:BrunswickAssociatesMember 2016-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2016-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2016-01-01 2016-03-31 0000798783 uht:GraysonPropertiesMember 2016-03-31 0000798783 uht:FTXMobPhaseTwoLPMember 2016-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2016-01-01 2016-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2015-01-01 2015-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2015-01-01 2015-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FtxMobPhaseTwoMember 2016-03-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2016-03-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FtxMobPhaseTwoMember 2015-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesMember 2015-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:BrunswickAssociatesMember 2015-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2015-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FtxMobPhaseTwoMember 2016-01-01 2016-03-31 0000798783 us-gaap:MinimumMember 2016-01-01 2016-03-31 0000798783 us-gaap:MaximumMember 2016-01-01 2016-03-31 0000798783 uht:NewRevolvingCreditFacilityAgreementMember 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember 2015-03-26 2015-03-27 0000798783 uht:PreviousRevolvingCreditFacilityMember 2015-03-26 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember us-gaap:LetterOfCreditMember 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember us-gaap:ShortTermDebtMember 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember 2016-01-01 2016-03-31 0000798783 uht:NewRevolvingCreditFacilityAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:MinimumMember 2015-03-26 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:MaximumMember 2015-03-26 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember us-gaap:BaseRateMember us-gaap:MinimumMember 2015-03-26 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember us-gaap:BaseRateMember us-gaap:MaximumMember 2015-03-26 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember uht:FederalFundsEffectiveRateMember us-gaap:MinimumMember 2015-03-26 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember us-gaap:MinimumMember 2015-03-26 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember us-gaap:MaximumMember 2015-03-26 2015-03-27 0000798783 uht:NewRevolvingCreditFacilityAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-03-30 2016-03-31 0000798783 uht:NewRevolvingCreditFacilityAgreementMember us-gaap:BaseRateMember 2016-03-30 2016-03-31 0000798783 uht:NewRevolvingCreditFacilityAgreementMember 2016-03-30 2016-03-31 0000798783 us-gaap:MaximumMember 2016-03-31 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeMortgageLoanMember 2016-03-31 0000798783 uht:PeaceHealthMedicalClinicFixedRateMortgageLoanMember 2016-03-31 0000798783 uht:AuburnMedicalTwoMortgageLoanMember 2016-03-31 0000798783 uht:MedicalCenterOfWesternConnecticutFixedRateMortgageLoanMember 2016-03-31 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingTwoMortgageLoanMember 2016-03-31 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2016-03-31 0000798783 uht:CentennialHillsMedicalOfficeBuildingOneMortgageLoanMember 2016-03-31 0000798783 uht:LomaVistaMedicalIncMember 2016-03-31 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2016-03-31 0000798783 uht:VibraHospitalOfCorpusChristiFixedRateMortgageLoanMember 2016-03-31 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingMortgageLoanMember 2016-03-31 0000798783 uht:BRBMedicalOfficeBuildingMortgageLoanMember 2016-03-31 0000798783 uht:DesertValleyMedicalCenterFloatingRateMortgageLoanMember 2016-03-31 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2016-03-31 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:PeaceHealthMedicalClinicFixedRateMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:AuburnMedicalTwoMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:MedicalCenterOfWesternConnecticutFixedRateMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingTwoMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:CentennialHillsMedicalOfficeBuildingOneMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:LomaVistaMedicalIncMember 2016-01-01 2016-03-31 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:VibraHospitalOfCorpusChristiFixedRateMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:BRBMedicalOfficeBuildingMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:DesertValleyMedicalCenterFloatingRateMortgageLoanMember 2016-01-01 2016-03-31 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2016-01-01 2016-03-31 0000798783 us-gaap:InterestRateCapMember 2013-09-30 0000798783 us-gaap:InterestRateCapMember 2014-03-31 0000798783 us-gaap:InterestRateCapMember 2013-07-01 2013-09-30 0000798783 us-gaap:InterestRateCapMember 2014-01-01 2014-03-31 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:InterestRateCapMember 2013-09-30 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:InterestRateCapMember 2014-03-31 10-Q false 2016-03-31 2016 Q1 UHT UNIVERSAL HEALTH REALTY INCOME TRUST 0000798783 --12-31 Accelerated Filer 13328083 4081000 3906000 8815000 8869000 1246000 1218000 1873000 2009000 211000 200000 16226000 16202000 5436000 5523000 767000 666000 4400000 4722000 82000 57000 10685000 10968000 5541000 5234000 1059000 592000 2172000 2130000 4428000 3696000 0.33 0.28 0.33 0.28 13307000 13283000 7000 11000 13314000 13294000 -2000 -61000 -23000 -23000 21000 -38000 4449000 3658000 478405000 469933000 125287000 121161000 353118000 348772000 44053000 41724000 397171000 390496000 36835000 31597000 4316000 3894000 2350000 2116000 4569000 4292000 19736000 19757000 6130000 6351000 471107000 458503000 159650000 142150000 109332000 110156000 538000 504000 6107000 6807000 4418000 3844000 280045000 263461000 133000 133000 241867000 241700000 559714000 555286000 610579000 601983000 -73000 -94000 191062000 195042000 471107000 458503000 23300000 25100000 0.01 0.01 5000000 5000000 0 0 0 0 0.01 0.01 95000000 95000000 13328033 13327020 13328033 13327020 5458000 5545000 -56000 -57000 111000 101000 64000 511000 194000 -1014000 -658000 574000 136000 -34000 48000 -70000 228000 9094000 8229000 5386000 321000 209000 147000 1045000 -1841000 -2168000 9910000 16765000 2250000 -16781000 -20459000 17500000 26250000 790000 5743000 35000 913000 8596000 8446000 30000 1172000 8109000 12320000 422000 90000 3861000 3951000 2072000 2115000 <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) General</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q is for the quarter ended March&#160;31, 2016. In this Quarterly Report, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Trust&#8221; refer to Universal Health Realty Income Trust and its subsidiaries.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this Quarterly Report on Form 10-Q, the term &#8220;revenues&#8221; does not include the revenues of the unconsolidated limited liability companies (&#8220;LLCs&#8221;) in which we have various non-controlling equity interests ranging from 33% to 95%.&nbsp;&nbsp;As of March 31, 2016, we had investments in five jointly-owned LLCs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December&#160;31, 2015.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div> <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) Relationship with Universal Health Services, Inc. (&#8220;UHS&#8221;) and Related Party Transactions</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases:<font style="font-style:normal;">&#160;We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each facility are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. These hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 25% of our consolidated revenues for each of the three months ended March&#160;31, 2016 and 2015. Including 100% of the revenues generated at the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%, the leases on the UHS hospital facilities accounted for approximately 20% of the combined consolidated and unconsolidated revenue for each of the three months ended March&#160;31, 2016 and 2015. In addition, we have sixteen medical office buildings (&#8220;MOBs&#8221;) or&#160; free-standing emergency departments (&#8220;FEDs&#8221;), that are either wholly or jointly-owned by us, include tenants which are subsidiaries of UHS.&nbsp;&nbsp; </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December&#160;24, 1986 (the &#8220;Master Lease&#8221;), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month&#8217;s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i)&#160;purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii)&#160;renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Hospital Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2016</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2016</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2016</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has three 5-year renewal options at existing lease rates (through 2031).</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has one 5-year renewal option at existing lease rates (through 2021) and two 5-year renewal options at fair market value lease rates (2022 through 2031).</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital and FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.&nbsp;&nbsp;The existing lease terms for our three acute care hospitals operated by wholly-owned subsidiaries of UHS are scheduled to expire in December, 2016 and we can provide no assurance that these leases will be renewed at the existing lease rates.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2016, we committed to invest up to $21.1 million in the development and construction of the Henderson Medical Plaza, an MOB located on the campus of the Henderson Hospital Medical Center which is owned by a UHS subsidiary and also currently under construction. The hospital and MOB are both scheduled to be completed and opened during the fourth quarter of 2016. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Advisory Agreement:<font style="font-style:normal;">&#160;UHS of Delaware, Inc. (the &#8220;Advisor&#8221;), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the &#8220;Advisory Agreement&#8221;) dated December&#160;24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the &#8220;Independent Trustees&#8221;). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December&#160;31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor&#8217;s performance has been satisfactory. In December of 2015, based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the Advisory agreement was renewed for 2016 pursuant to the same terms as the Advisory Agreement in place during 2015.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid during the first three months of 2016 or 2015 since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $767,000 and $666,000 for the three months ended March&#160;31, 2016 and 2015, respectively, and were based upon average invested real estate assets of $438&#160;million and $381 million for the three-month periods ended March&#160;31, 2016 and 2015, respectively. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Officers and Employees:<font style="font-style:normal;"> Our officers are all employees of a wholly-owned subsidiary of UHS and although as of March&#160;31, 2016 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share Ownership:<font style="font-style:normal;"> As of March&#160;31, 2016 and December&#160;31, 2015, UHS owned 5.9% of our outstanding shares of beneficial interest.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">SEC reporting requirements of UHS:<font style="font-style:normal;"> UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the leases on the hospital facilities leased to wholly-owned subsidiaries of UHS comprised approximately 25% of our consolidated revenues during each of the three month periods ended March&#160;31, 2016 and 2015, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC&#8217;s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.</font></p></div> <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(3) Dividends and Equity Issuance Program</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We declared and paid dividends of $8.6 million, or $.645 per share, during the first quarter of 2016 and $8.4 million, or $.635 per share, during the first quarter of 2015. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Issuance Program:</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to the first quarter of 2016, we recommenced our at-the-market (&#8220;ATM&#8221;) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of approximately&nbsp;&nbsp;$23.3 million to or through Merrill Lynch, Pierce, Fenner and Smith, Incorporated (&#8220;Merrill Lynch&#8221;), as sales agent and/or principal. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective in December, 2015.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no shares issued pursuant to the ATM program during the first three months of 2016. Since inception of this ATM program, we have issued 580,900 shares at an average price of $45.97 per share, which generated approximately $25.6 million of net proceeds (net of approximately $1.1 million, consisting of compensation of $667,000 to Merrill Lynch as well as $391,000 of other various fees and expenses). Included in cash received for the issuance of shares of beneficial interest, net, on the Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2015, was approximately $1.1 million received in connection with shares issued in late December, 2014.</p></div> <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) Acquisitions, Dispositions and New Construction</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2016:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acquisition:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March, 2016, we purchased the Madison Professional Office Building located in Madison, Alabama for approximately $10.1 million. This multi-tenant property consists of approximately 30,100 rentable square feet and is fully occupied with an average remaining lease term of approximately 6.2 years at the time of acquisition.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate purchase price for this MOB was allocated to the assets acquired and liabilities assumed consisting of tangible property and identified intangible assets, based on the fair value estimated at acquisition as detailed in the table below. Substantially all of the intangible assets include the value of the in-place leases at the MOB at the time of acquisition which will be amortized over the average remaining lease term of approximately 6.2 years at the time of acquisition. </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.74%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:432pt;;"> <tr> <td style="width:367.5pt;"></td> <td style="width:64.5pt;"></td> </tr> <tr> <td valign="middle" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td> <td valign="middle" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td> </tr> <tr> <td valign="top" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2,328</p></td> </tr> <tr> <td valign="top" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings and improvements</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,523</p></td> </tr> <tr> <td valign="top" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,209</p></td> </tr> <tr> <td valign="top" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposit </p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150)</p></td> </tr> <tr> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td> </tr> <tr> <td valign="top" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash paid</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$9,910</p></td> </tr> <tr> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="border-top:Double 2.25pt;padding-top:1pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">New Construction:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2016, we committed to invest up to $21.1 million in the development and construction of the Henderson Medical Plaza, an MOB located on the campus of the Henderson Hospital Medical Center which is owned by a UHS subsidiary and also currently under construction. The hospital and MOB are both scheduled to be completed and opened during the fourth quarter of 2016. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dispositions:&nbsp;&nbsp;</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no divestitures during the first three months of 2016.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2015:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acquisitions:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February, 2015, we purchased the Haas Medical Office Park, two single story buildings having an aggregate of approximately 16,000 rentable square feet, located in Ottumwa, Iowa, for approximately $4.1 million.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January and February of 2015, we purchased from wholly-owned subsidiaries of UHS, the real property of two newly-constructed and recently opened FEDs located in Weslaco and Mission, Texas, for an aggregate acquisition cost of approximately $12.8 million. Each FED consists of approximately 13,600 square feet and is operated by wholly-owned subsidiaries of UHS. In connection with these acquisitions, ten-year lease agreements with six 5-year renewal terms were executed with UHS for each FED. In connection with the lease agreements, the lessee shall have the option to purchase the leased property upon the expiration of the fixed term and each five-year extended term at the fair market value at that time.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dispositions:&nbsp;&nbsp;</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no divestitures during the first three months of 2015.</p></div> <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(5) Summarized Financial Information of Equity Affiliates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.&nbsp;&nbsp;The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i)&#160;divestiture of property; (ii)&#160;annual budget approval, and; (iii)&#160;financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2016, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. As of March&#160;31, 2016, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that manage and hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective February 1, 2016, we purchased an additional 10% ownership interest in the Arlington Medical Properties, LLC from the third-party minority member, subject to certain agreed upon terms and conditions. Including this additional ownership interest, we currently own 85% of this LLC which is accounted for on an unconsolidated basis pursuant to the equity method.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following property table represents the five LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of March&#160;31, 2016:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arlington Medical Properties (b.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Saint Mary&#8217;s Professional Office Building</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (c.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (d.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</p></td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of March&#160;31, 2016.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have funded $5.2 million in equity as of March 31, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date.&nbsp;&nbsp;The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%. </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have funded $2.8 million in equity as of March&#160;31, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.6 million outstanding as of March&#160;31, 2016.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have committed to invest up to $2.5 million in equity and debt financing, of which $2.0 million has been funded as of March&#160;31, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.4 million outstanding as of March&#160;31, 2016.</p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;Below are the condensed combined statements of income (unaudited) for the LLCs accounted for under the equity method at March 31, 2016 and 2015.&nbsp;&nbsp; </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.5%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,736</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,585</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,353</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,337</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">657</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">619</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,113</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,049</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,059</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our share of net income for the three months ended March 31, 2016 includes interest income earned by us on an advance made to Arlington Medical Properties, LLC of approximately $296,000. There were no advances outstanding during the first three months of 2015, therefore there was no interest income earned by us for the three months ended March&#160;31, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015. </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs in which we hold noncontrolling ownership interests and that were accounted for under the equity method as of March&#160;31, 2016 and December&#160;31, 2015:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including CIP</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,838</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,668</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,415</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,264</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,253</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,932</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,657</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,763</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,895</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advances payable to us</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,280</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,489</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,553</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,010</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,253</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,932</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in&nbsp;&nbsp;and advances to LLCs reflected as:</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Investments in LLCs (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,555</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,108</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Advances to LLCs</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,280</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,489</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal-Investments in and advances to LLCs before</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; amounts included in accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,835</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,597</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Amounts included in accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,311</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,105</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in and advances to LLCs, net</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,524</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,492</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">As mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.</p></td></tr></table></div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2016, and December&#160;31, 2015, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3/31/2016</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2015</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,396</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,427</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August, 2017</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,612</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,670</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,755</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,798</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2024</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,763</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,895</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All mortgage loans, other than construction loans, require monthly principal payments through maturity and include a balloon principal payment upon maturity.</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (&#8220;Offering Member&#8221;) to the other member(s) (&#8220;Non-Offering Member&#8221;) in which it either agrees to: (i)&#160;sell the entire ownership interest of the Offering Member to the Non-Offering Member (&#8220;Offer to Sell&#8221;) at a price as determined by the Offering Member (&#8220;Transfer Price&#8221;), or; (ii)&#160;purchase the entire ownership interest of the Non-Offering Member (&#8220;Offer to Purchase&#8221;) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i)&#160;purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii)&#160;sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div> <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6) Recent Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March, 2016, the FASB issued ASU 2016-07, <font style="font-style:italic;">Investments &#8211; Equity Method and Joint Ventures (Topic 323):</font> <font style="font-style:italic;">Simplifying the Transition to the Equity Method of Accounting, </font>which requires an investor to initially apply the equity method of accounting from the date it qualified for that method.&nbsp;&nbsp;The ASU eliminates the previous requirement to retroactively adjust the investment and record a cumulative catch up for the periods that the investment had been held, but did not qualify for the equity method of accounting.&nbsp;&nbsp;The amendments are effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted.&nbsp;&nbsp;We are currently in the process of evaluating the impact of adoption of this ASU on our consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the <font style="font-family:Times New Roman;">Financial Accounting Standards Board (&#8220;FASB&#8221;)</font> issued ASU 2016-02, Leases (Topic 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASU 2016-02 supersedes the previous leases standard, Leases (Topic 840). The standard is effective on January 1, 2019, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of ASU 2016-02 will have on our financial position or results of operations.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2015, the FASB issued&#160;ASU No. 2015-03,&#160;Simplifying the Presentation of Debt Issuance Costs, an update to the accounting standard relating to the presentation of debt issuance costs. Under the new guidance, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability. In the event that there is not an associated debt liability recorded in the consolidated financial statements, the debt issuance costs will continue to be recorded on the consolidated balance sheet as an asset until the debt liability is recorded.&#160;&#160;The new standard became effective for the Trust on January 1, 2016. The adoption of this guidance did not have a material impact on our consolidated financial position or results of operations as the update only related to changes in financial statement presentation.&nbsp;&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2015, the FASB issued ASU No. 2015-02, Consolidation &#8211; Amendments to the Consolidation Analysis, which amends the current consolidation guidance affecting both the variable interest entity (&#8220;VIE&#8221;) and voting interest entity (&#8220;VOE&#8221;) consolidation models. The standard does not add or remove any of the characteristics in determining if an entity is a VIE or VOE, but rather enhances the way the Company assesses some of these characteristics. The new standard became effective for the Trust on January 1, 2016 and did not have a material impact on our consolidated financial position or results of operations as none of its existing consolidation conclusions were changed.</p></div> <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(7) Debt and Financial Instruments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Debt:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management routinely monitors and analyzes the Trust&#8217;s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $185 million revolving credit facility, the level of borrowings pursuant to non-course mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our at-the-market equity issuance program.&nbsp;&nbsp;This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust&#8217;s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust&#8217;s current balance of revolving credit facility borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust&#8217;s growth.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;27, 2015, we entered into a new $185 million revolving credit agreement (&#8220;Credit Agreement&#8221;). The Credit Agreement, which will mature in March, 2019, replaced our previous revolving credit facility which was scheduled to mature in July, 2015. The Credit Agreement includes a $50 million sub limit for letters of credit and a $20 million sub limit for swingline/short-term loans. The Credit Agreement also provides a one-time option to extend the maturity date for an additional one year period, and an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement. Borrowings under the new facility are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the new facility are secured by first priority security interests in and liens on all equity interests in the Trust&#8217;s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.50% to 2.00% or at the Base Rate plus an applicable margin ranging from 0.50% to 1.00%. The Credit Agreement defines &#8220;Base Rate&#8221; as the greatest of: (a)&#160;the administrative agent&#8217;s prime rate; (b)&#160;the federal funds effective rate plus 1/2 of 1%, and; (c)&#160;one month LIBOR plus 1%. A commitment fee of 0.20% to 0.40% (depending on our total leverage ratio) will be charged on the average unused portion of the revolving credit commitments. The margins over LIBOR, Base Rate and the commitment fee are based upon our ratio of debt to total capital. At March&#160;31, 2016, the applicable margin over the LIBOR rate was 1.625%, the margin over the Base Rate was 0.625%, and the commitment fee was 0.25%.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2016, we had $159.7 million of outstanding borrowings and $3.0 million of letters of credit outstanding against our revolving credit agreement. We had $22.3 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2016. At December&#160;31, 2015, we had $142.2 million of outstanding borrowings and $3.5 million of letters of credit outstanding against our revolving credit agreement. We had $39.3 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of December&#160;31, 2015. There are no compensating balance requirements.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust&#8217;s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2016. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,326</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.6</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 30%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.4</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.2</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&gt; 1.50x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As indicated on the following table, we have fourteen mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March&#160;31, 2016, with a combined outstanding balance of $109.5 million, excluding net debt premium of $242,000 and net of net financing fees of $376,000 (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Facility Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<font style="font-family:Calibri;">&#160;</font>thousands)(a)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; floating rate mortgage loan (b.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,616</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.69</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December,&#160;2016</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peace Health fixed rate mortgage loan (b.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,671</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.64</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April,&#160;2017</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auburn Medical II floating rate mortgage loan (b.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,897</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.19</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April,&#160;2017</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Center of Western Connecticut fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,631</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2017</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building II fixed</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,339</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October,&#160;2017</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children&#8217;s East Valley Care Center fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,312</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December,&#160;2017</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centennial Hills Medical Office Building floating rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,266</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.69</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January,&#160;2018</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sparks Medical Building/Vista Medical Terrace</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; floating rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,320</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.69</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February,&#160;2018</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosenberg Children&#8217;s Medical Plaza fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,275</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.85</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May,&#160;2018</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vibra Hospital-Corpus Christi fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,793</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.50</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July,&#160;2019</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,384</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,453</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,179</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January,&#160;2023</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,330</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2025</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,466</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.66%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.66%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our revolving credit facility. </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages have a combined fair value of approximately $112 million as of March 31, 2016. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2015, we had fourteen mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these fourteen mortgages was $110.3 million (excluding net debt premium of $298,000 and net of net financing fees of $398,000), and had a combined fair value of approximately $112.4 million.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financial Instruments:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the third quarter of 2013, we entered into an interest rate cap on a total notional amount of $10 million whereby we paid a premium of $136,000. During the first quarter of 2014, we entered into two additional interest rate cap agreements on a total notional amount of $20&#160;million whereby we paid premiums of $134,500. In exchange for the premium payments, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap. From inception through March&#160;31, 2016, no payments have been made to us by the counterparties pursuant to the terms of these caps which expire in January, 2017.</p></div> <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(8) Segment Reporting</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Hospital Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2016</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2016</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2016</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has three 5-year renewal options at existing lease rates (through 2031).</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has one 5-year renewal option at existing lease rates (through 2021) and two 5-year renewal options at fair market value lease rates (2022 through 2031).</p></td></tr></table></div></div> <div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate purchase price for this MOB was allocated to the assets acquired and liabilities assumed consisting of tangible property and identified intangible assets, based on the fair value estimated at acquisition as detailed in the table below. Substantially all of the intangible assets include the value of the in-place leases at the MOB at the time of acquisition which will be amortized over the average remaining lease term of approximately 6.2 years at the time of acquisition. </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.74%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:432pt;;"> <tr> <td style="width:367.5pt;"></td> <td style="width:64.5pt;"></td> </tr> <tr> <td valign="middle" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td> <td valign="middle" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td> </tr> <tr> <td valign="top" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2,328</p></td> </tr> <tr> <td valign="top" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings and improvements</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,523</p></td> </tr> <tr> <td valign="top" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,209</p></td> </tr> <tr> <td valign="top" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deposit </p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(150)</p></td> </tr> <tr> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td> </tr> <tr> <td valign="top" style=""> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash paid</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$9,910</p></td> </tr> <tr> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="border-top:Double 2.25pt;padding-top:1pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following property table represents the five LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of March&#160;31, 2016:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arlington Medical Properties (b.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Saint Mary&#8217;s Professional Office Building</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (c.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (d.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</p></td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of March&#160;31, 2016.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have funded $5.2 million in equity as of March 31, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date.&nbsp;&nbsp;The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%. </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have funded $2.8 million in equity as of March&#160;31, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.6 million outstanding as of March&#160;31, 2016.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have committed to invest up to $2.5 million in equity and debt financing, of which $2.0 million has been funded as of March&#160;31, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.4 million outstanding as of March&#160;31, 2016.</p></td></tr></table></div></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined statements of income (unaudited) for the LLCs accounted for under the equity method at March 31, 2016 and 2015.&nbsp;&nbsp; </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.5%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,736</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,585</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,353</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,337</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">657</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">619</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,113</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,049</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,059</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our share of net income for the three months ended March 31, 2016 includes interest income earned by us on an advance made to Arlington Medical Properties, LLC of approximately $296,000. There were no advances outstanding during the first three months of 2015, therefore there was no interest income earned by us for the three months ended March&#160;31, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015. </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs in which we hold noncontrolling ownership interests and that were accounted for under the equity method as of March&#160;31, 2016 and December&#160;31, 2015:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including CIP</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,838</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,668</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,415</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,264</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,253</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,932</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,657</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,763</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,895</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advances payable to us</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,280</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,489</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,553</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,010</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,253</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,932</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in&nbsp;&nbsp;and advances to LLCs reflected as:</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Investments in LLCs (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,555</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,108</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Advances to LLCs</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,280</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,489</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal-Investments in and advances to LLCs before</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; amounts included in accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,835</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,597</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Amounts included in accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,311</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,105</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in and advances to LLCs, net</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,524</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,492</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">As mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.</p></td></tr></table></div></div> <div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2016, and December&#160;31, 2015, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3/31/2016</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2015</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,396</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,427</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August, 2017</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,612</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,670</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,755</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,798</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2024</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,763</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,895</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All mortgage loans, other than construction loans, require monthly principal payments through maturity and include a balloon principal payment upon maturity.</p></td></tr></table></div></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,326</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.6</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 30%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.4</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.2</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&gt; 1.50x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div> <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Facility Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<font style="font-family:Calibri;">&#160;</font>thousands)(a)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; floating rate mortgage loan (b.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,616</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.69</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December,&#160;2016</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peace Health fixed rate mortgage loan (b.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,671</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.64</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April,&#160;2017</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auburn Medical II floating rate mortgage loan (b.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,897</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.19</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April,&#160;2017</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Center of Western Connecticut fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,631</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2017</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building II fixed</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,339</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October,&#160;2017</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children&#8217;s East Valley Care Center fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,312</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December,&#160;2017</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centennial Hills Medical Office Building floating rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,266</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.69</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January,&#160;2018</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sparks Medical Building/Vista Medical Terrace</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; floating rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,320</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.69</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February,&#160;2018</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosenberg Children&#8217;s Medical Plaza fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,275</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.85</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May,&#160;2018</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vibra Hospital-Corpus Christi fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,793</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.50</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July,&#160;2019</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,384</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,453</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,179</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January,&#160;2023</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,330</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2025</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,466</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.66%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.66%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our revolving credit facility. </p></td></tr></table></div></div> 0.33 0.95 5 P13Y P15Y 6 P5Y 0.25 0.25 0.20 0.20 16 P90D P180D P180D 5485000 3030000 2648000 2016-12 2016-12 2016-12 P15Y P15Y P15Y 3 P5Y 2031 1 P5Y 2021 2 P5Y 2022 2031 21100000 0.20 0.15 0 0 767000 666000 438000000 381000000 0.059 0.059 0.645 0.635 23300000 0 580900 45.97 25600000 1100000 667000 391000 1100000 30100 P6Y2M12D 10100000 P6Y2M12D 2328000 6523000 1209000 150000 9910000 0 2 16000 4100000 2 12800000 13600 P10Y 6 P5Y 0 0.33 0.95 5 0.10 0.85 0.33 0.74 0.85 0.95 0.95 St. Matthews Medical Plaza II Mid Coast Hospital MOB Saint Mary’s Professional Office Building Texoma Medical Plaza Forney Medical Plaza II 8700000 5200000 623000 22800000 0.10 4800000 0.85 2800000 100000 14600000 2000000 2500000 5400000 3736000 3585000 1353000 1337000 613000 580000 657000 619000 1113000 1049000 296000 0 0.85 0.75 61838000 61668000 5415000 5264000 67253000 66932000 2657000 2538000 28763000 28895000 22280000 22489000 13553000 13010000 67253000 66932000 14555000 9108000 22280000 22489000 1311000 1105000 35524000 30492000 5396000 14612000 8755000 28763000 5427000 14670000 8798000 28895000 2017-08 2021-09 2024-12 P60D P90D 185000000 2019-03 2015-07 50000000 20000000 1 50000000 One, two, three, or six month LIBOR plus an applicable margin ranging from 1.50% to 2.00% or at the Base Rate plus an applicable margin ranging from 0.50% to 1.00%. 0.0150 0.01 0.0200 0.0050 0.0100 The greatest of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%. 0.0050 0.0020 0.0040 0.01625 0.00625 0.0025 125000000 0.60 0.30 0.60 0.0150 171326000 0.466 0.194 0.462 0.035 10616000 20671000 6897000 4631000 11339000 6312000 10266000 4320000 8275000 2793000 6384000 6453000 5179000 5330000 109466000 0.0369 0.0564 0.0319 0.0600 0.0550 0.0588 0.0369 0.0369 0.0485 0.0650 0.0454 0.0427 0.0362 0.0556 2016-12 2017-04 2017-04 2017-06 2017-10 2017-12 2018-01 2018-02 2018-05 2019-07 2022-06 2022-12 2023-01 2025-06 112000000 14 110300000 298000 112400000 398000 1 2 10000000 20000000 136000 134500 2017-01-31 2017-01-31 0.0150 0.0150 1 3 2016-12 3000000 3500000 22300000 39300000 14 242000000 376000000 UHS has three 5-year renewal options at existing lease rates (through 2031). UHS has one 5-year renewal option at existing lease rates (through 2021) and two 5-year renewal options at fair market value lease rates (2022 through 2031). This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of March 31, 2016. We have funded $5.2 million in equity as of March 31, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date. The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%. We have funded $2.8 million in equity as of March 31, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.6 million outstanding as of March 31, 2016. We have committed to invest up to $2.5 million in equity and debt financing, of which $2.0 million has been funded as of March 31, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.4 million outstanding as of March 31, 2016. Our share of net income for the three months ended March 31, 2016 includes interest income earned by us on an advance made to Arlington Medical Properties, LLC of approximately $296,000. There were no advances outstanding during the first three months of 2015, therefore there was no interest income earned by us for the three months ended March 31, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015. As mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015. All mortgage loans, other than construction loans, require monthly principal payments through maturity and include a balloon principal payment upon maturity. All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our revolving credit facility. EX-101.SCH 7 uht-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Statements of Income link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statement of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - General link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Dividends and Equity Issuance Program link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Acquisitions, Dispositions and New Construction link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Summarized Financial Information of Equity Affiliates link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Debt and Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Acquisitions, Dispositions and New Construction (Tables) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Debt and Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - General - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Acquisitions, Dispositions and New Construction - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Segment Reporting - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 uht-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 uht-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 uht-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 uht-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2016
Apr. 30, 2016
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q1  
Trading Symbol UHT  
Entity Registrant Name UNIVERSAL HEALTH REALTY INCOME TRUST  
Entity Central Index Key 0000798783  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   13,328,083
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenues:    
Base rental - UHS facilities $ 4,081 $ 3,906
Base rental - Non-related parties 8,815 8,869
Bonus rental - UHS facilities 1,246 1,218
Tenant reimbursements and other - Non-related parties 1,873 2,009
Tenant reimbursements and other - UHS facilities 211 200
Revenues, Total 16,226 16,202
Expenses:    
Depreciation and amortization 5,436 5,523
Advisory fees to UHS 767 666
Other operating expenses 4,400 4,722
Transaction costs 82 57
Costs and Expenses, Total 10,685 10,968
Income before equity in income of unconsolidated limited liability companies ("LLCs"), and interest expense 5,541 5,234
Equity in income of unconsolidated LLCs [1] 1,059 592
Interest expense, net (2,172) (2,130)
Net income $ 4,428 $ 3,696
Basic earnings per share $ 0.33 $ 0.28
Diluted earnings per share $ 0.33 $ 0.28
Weighted average number of shares outstanding – Basic 13,307 13,283
Weighted average number of share equivalents 7 11
Weighted average number of shares and equivalents outstanding – Diluted 13,314 13,294
[1] Our share of net income for the three months ended March 31, 2016 includes interest income earned by us on an advance made to Arlington Medical Properties, LLC of approximately $296,000. There were no advances outstanding during the first three months of 2015, therefore there was no interest income earned by us for the three months ended March 31, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]    
Net Income $ 4,428 $ 3,696
Other comprehensive income/(loss):    
Unrealized derivative losses on interest rate caps (2) (61)
Amortization of interest rate cap fees 23 23
Total other comprehensive income/(loss): 21 (38)
Total comprehensive income $ 4,449 $ 3,658
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Real Estate Investments:    
Buildings and improvements $ 478,405 $ 469,933
Accumulated depreciation (125,287) (121,161)
Real Estate Investment Property, Net, Total 353,118 348,772
Land 44,053 41,724
Net Real Estate Investments 397,171 390,496
Investments in and advances to limited liability companies ("LLCs") 36,835 31,597
Other Assets:    
Cash and cash equivalents 4,316 3,894
Base and bonus rent receivable from UHS 2,350 2,116
Rent receivable - other 4,569 4,292
Intangible assets (net of accumulated amortization of $23.3 million and $25.1 million at March 31, 2016 and December 31, 2015, respectively) 19,736 19,757
Deferred charges and other assets, net 6,130 6,351
Total Assets 471,107 458,503
Liabilities:    
Line of credit borrowings 159,650 142,150
Mortgage and other notes payable, non-recourse to us, net 109,332 110,156
Accrued interest 538 504
Accrued expenses and other liabilities 6,107 6,807
Tenant reserves, escrows, deposits and prepaid rents 4,418 3,844
Total Liabilities $ 280,045 $ 263,461
Equity:    
Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding
Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2016 - 13,328,033; 2015 -13,327,020 $ 133 $ 133
Capital in excess of par value 241,867 241,700
Cumulative net income 559,714 555,286
Cumulative dividends (610,579) (601,983)
Accumulated other comprehensive loss (73) (94)
Total Equity 191,062 195,042
Total Liabilities and Equity $ 471,107 $ 458,503
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2016
Dec. 31, 2015
Statement Of Financial Position [Abstract]    
Intangible assets, accumulated amortization $ 23.3 $ 25.1
Preferred shares of beneficial interest, par value $ 0.01 $ 0.01
Preferred shares of beneficial interest, shares authorized 5,000,000 5,000,000
Preferred shares of beneficial interest, issued 0 0
Preferred shares of beneficial interest, outstanding 0 0
Common shares, par value $ 0.01 $ 0.01
Common shares, shares authorized 95,000,000 95,000,000
Common shares, issued 13,328,033 13,327,020
Common shares, outstanding 13,328,033 13,327,020
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statement of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities:    
Net Income $ 4,428 $ 3,696
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 5,458 5,545
Amortization of debt premium (56) (57)
Stock-based compensation expense 111 101
Income in excess of cash distributions from LLCs   (64)
Changes in assets and liabilities:    
Rent receivable (511) (194)
Accrued expenses and other liabilities (1,014) (658)
Tenant reserves, escrows, deposits and prepaid rents 574 136
Accrued interest 34 (48)
Other, net 70 (228)
Net cash provided by operating activities 9,094 8,229
Cash flows from investing activities:    
Investments in LLCs (5,386) (321)
Repayments of advances made to LLC 209  
Cash distributions in excess of income from LLCs 147  
Cash distribution of refinancing proceeds from LLCs   1,045
Additions to real estate investments, net (1,841) (2,168)
Net cash paid for acquisition of properties (9,910) (16,765)
Cash paid to acquire minority interests in majority-owned LLCs   (2,250)
Net cash used in investing activities (16,781) (20,459)
Cash flows from financing activities:    
Net borrowings on line of credit 17,500 26,250
Repayments of mortgages and other notes payable (790) (5,743)
Financing costs paid (35) (913)
Dividends paid (8,596) (8,446)
Issuance of shares of beneficial interest, net 30 1,172
Net cash provided by financing activities 8,109 12,320
Increase in cash and cash equivalents 422 90
Cash and cash equivalents, beginning of period 3,894 3,861
Cash and cash equivalents, end of period 4,316 3,951
Supplemental disclosures of cash flow information:    
Interest paid $ 2,072 $ 2,115
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
General
3 Months Ended
Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
General

(1) General

This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2016. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%.  As of March 31, 2016, we had investments in five jointly-owned LLCs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.

The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2015.

 

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions
3 Months Ended
Mar. 31, 2016
Related Party Transactions [Abstract]  
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each facility are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. These hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 25% of our consolidated revenues for each of the three months ended March 31, 2016 and 2015. Including 100% of the revenues generated at the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%, the leases on the UHS hospital facilities accounted for approximately 20% of the combined consolidated and unconsolidated revenue for each of the three months ended March 31, 2016 and 2015. In addition, we have sixteen medical office buildings (“MOBs”) or  free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us, include tenants which are subsidiaries of UHS.  

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month’s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.

 

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2016

 

 

15

 

(a)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2016

 

 

15

 

(b)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2016

 

 

15

 

(b)

 

(a)

UHS has three 5-year renewal options at existing lease rates (through 2031).

(b)

UHS has one 5-year renewal option at existing lease rates (through 2021) and two 5-year renewal options at fair market value lease rates (2022 through 2031).

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital and FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.  The existing lease terms for our three acute care hospitals operated by wholly-owned subsidiaries of UHS are scheduled to expire in December, 2016 and we can provide no assurance that these leases will be renewed at the existing lease rates.

During the first quarter of 2016, we committed to invest up to $21.1 million in the development and construction of the Henderson Medical Plaza, an MOB located on the campus of the Henderson Hospital Medical Center which is owned by a UHS subsidiary and also currently under construction. The hospital and MOB are both scheduled to be completed and opened during the fourth quarter of 2016.

Advisory Agreement: UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the “Advisory Agreement”) dated December 24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. In December of 2015, based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the Advisory agreement was renewed for 2016 pursuant to the same terms as the Advisory Agreement in place during 2015.

The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid during the first three months of 2016 or 2015 since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $767,000 and $666,000 for the three months ended March 31, 2016 and 2015, respectively, and were based upon average invested real estate assets of $438 million and $381 million for the three-month periods ended March 31, 2016 and 2015, respectively.

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of March 31, 2016 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

Share Ownership: As of March 31, 2016 and December 31, 2015, UHS owned 5.9% of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the leases on the hospital facilities leased to wholly-owned subsidiaries of UHS comprised approximately 25% of our consolidated revenues during each of the three month periods ended March 31, 2016 and 2015, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
Dividends and Equity Issuance Program
3 Months Ended
Mar. 31, 2016
Equity [Abstract]  
Dividends and Equity Issuance Program

(3) Dividends and Equity Issuance Program

Dividends:

We declared and paid dividends of $8.6 million, or $.645 per share, during the first quarter of 2016 and $8.4 million, or $.635 per share, during the first quarter of 2015.

Equity Issuance Program:

Subsequent to the first quarter of 2016, we recommenced our at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of approximately  $23.3 million to or through Merrill Lynch, Pierce, Fenner and Smith, Incorporated (“Merrill Lynch”), as sales agent and/or principal. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective in December, 2015.

There were no shares issued pursuant to the ATM program during the first three months of 2016. Since inception of this ATM program, we have issued 580,900 shares at an average price of $45.97 per share, which generated approximately $25.6 million of net proceeds (net of approximately $1.1 million, consisting of compensation of $667,000 to Merrill Lynch as well as $391,000 of other various fees and expenses). Included in cash received for the issuance of shares of beneficial interest, net, on the Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2015, was approximately $1.1 million received in connection with shares issued in late December, 2014.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
Acquisitions, Dispositions and New Construction
3 Months Ended
Mar. 31, 2016
Business Combinations [Abstract]  
Acquisitions, Dispositions and New Construction

(4) Acquisitions, Dispositions and New Construction

Three Months Ended March 31, 2016:

Acquisition:

In March, 2016, we purchased the Madison Professional Office Building located in Madison, Alabama for approximately $10.1 million. This multi-tenant property consists of approximately 30,100 rentable square feet and is fully occupied with an average remaining lease term of approximately 6.2 years at the time of acquisition.

 

The aggregate purchase price for this MOB was allocated to the assets acquired and liabilities assumed consisting of tangible property and identified intangible assets, based on the fair value estimated at acquisition as detailed in the table below. Substantially all of the intangible assets include the value of the in-place leases at the MOB at the time of acquisition which will be amortized over the average remaining lease term of approximately 6.2 years at the time of acquisition.

 

 

 

Land

$2,328

Buildings and improvements

6,523

Intangible assets

1,209

Deposit

(150)

 

 

Net cash paid

$9,910

 

 

New Construction:

During the first quarter of 2016, we committed to invest up to $21.1 million in the development and construction of the Henderson Medical Plaza, an MOB located on the campus of the Henderson Hospital Medical Center which is owned by a UHS subsidiary and also currently under construction. The hospital and MOB are both scheduled to be completed and opened during the fourth quarter of 2016.

Dispositions:  

There were no divestitures during the first three months of 2016.

Three Months Ended March 31, 2015:

Acquisitions:

In February, 2015, we purchased the Haas Medical Office Park, two single story buildings having an aggregate of approximately 16,000 rentable square feet, located in Ottumwa, Iowa, for approximately $4.1 million.

In January and February of 2015, we purchased from wholly-owned subsidiaries of UHS, the real property of two newly-constructed and recently opened FEDs located in Weslaco and Mission, Texas, for an aggregate acquisition cost of approximately $12.8 million. Each FED consists of approximately 13,600 square feet and is operated by wholly-owned subsidiaries of UHS. In connection with these acquisitions, ten-year lease agreements with six 5-year renewal terms were executed with UHS for each FED. In connection with the lease agreements, the lessee shall have the option to purchase the leased property upon the expiration of the fixed term and each five-year extended term at the fair market value at that time.

Dispositions:  

There were no divestitures during the first three months of 2015.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summarized Financial Information of Equity Affiliates
3 Months Ended
Mar. 31, 2016
Equity Method Investments And Joint Ventures [Abstract]  
Summarized Financial Information of Equity Affiliates

(5) Summarized Financial Information of Equity Affiliates

In accordance with the Financial Accounting Standards Board’s (“FASB”) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

At March 31, 2016, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. As of March 31, 2016, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that manage and hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties.

Effective February 1, 2016, we purchased an additional 10% ownership interest in the Arlington Medical Properties, LLC from the third-party minority member, subject to certain agreed upon terms and conditions. Including this additional ownership interest, we currently own 85% of this LLC which is accounted for on an unconsolidated basis pursuant to the equity method.

 

The following property table represents the five LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of March 31, 2016:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)

 

 

74

%

 

Mid Coast Hospital MOB

Arlington Medical Properties (b.)

 

 

85

%

 

Saint Mary’s Professional Office Building

Grayson Properties (c.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (d.)

 

 

95

%

 

Forney Medical Plaza II

 

(a.)

This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of March 31, 2016.

(b.)

We have funded $5.2 million in equity as of March 31, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date.  The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%.

(c.)

We have funded $2.8 million in equity as of March 31, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.6 million outstanding as of March 31, 2016.

(d.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.0 million has been funded as of March 31, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.4 million outstanding as of March 31, 2016.

 Below are the condensed combined statements of income (unaudited) for the LLCs accounted for under the equity method at March 31, 2016 and 2015.  

 

 

 

Three Months Ended

March 31,

 

 

 

 

2016

 

 

2015

 

 

 

 

(amounts in thousands)

Revenues

 

$

3,736

 

 

$

3,585

 

 

Operating expenses

 

 

1,353

 

 

 

1,337

 

 

Depreciation and amortization

 

 

613

 

 

 

580

 

 

Interest, net

 

 

657

 

 

 

619

 

 

Net income

 

$

1,113

 

 

$

1,049

 

 

Our share of net income (a.)

 

$

1,059

 

 

$

592

 

 

 

(a.)

Our share of net income for the three months ended March 31, 2016 includes interest income earned by us on an advance made to Arlington Medical Properties, LLC of approximately $296,000. There were no advances outstanding during the first three months of 2015, therefore there was no interest income earned by us for the three months ended March 31, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.

 

Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs in which we hold noncontrolling ownership interests and that were accounted for under the equity method as of March 31, 2016 and December 31, 2015:

 

 

 

March 31,

2016

 

 

December 31,

2015

 

 

 

(amounts in thousands)

 

Net property, including CIP

 

$

61,838

 

 

$

61,668

 

Other assets

 

 

5,415

 

 

 

5,264

 

Total assets

 

$

67,253

 

 

$

66,932

 

 

 

 

 

 

 

 

 

 

Liabilities

 

$

2,657

 

 

$

2,538

 

Mortgage notes payable, non-recourse to us

 

 

28,763

 

 

 

28,895

 

Advances payable to us

 

 

22,280

 

 

 

22,489

 

Equity

 

 

13,553

 

 

 

13,010

 

Total liabilities and equity

 

$

67,253

 

 

$

66,932

 

 

 

 

 

 

 

 

 

 

Our share of equity in  and advances to LLCs reflected as:

 

 

 

 

 

 

 

 

   Investments in LLCs (a.)

 

$

14,555

 

 

$

9,108

 

   Advances to LLCs

 

 

22,280

 

 

 

22,489

 

Subtotal-Investments in and advances to LLCs before

 

 

 

 

 

 

 

 

   amounts included in accrued expenses and other liabilities

 

 

36,835

 

 

 

31,597

 

   Amounts included in accrued expenses and other liabilities

 

 

(1,311

)

 

 

(1,105

)

Our share of equity in and advances to LLCs, net

 

$

35,524

 

 

$

30,492

 

 

 

(a.)

As mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.

 

As of March 31, 2016, and December 31, 2015, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

3/31/2016

 

 

12/31/2015

 

 

Maturity Date

FTX MOB Phase II

 

$

5,396

 

 

$

5,427

 

 

August, 2017

Grayson Properties

 

 

14,612

 

 

 

14,670

 

 

September, 2021

Brunswick Associates

 

 

8,755

 

 

 

8,798

 

 

December, 2024

 

 

$

28,763

 

 

$

28,895

 

 

 

 

(a.)

All mortgage loans, other than construction loans, require monthly principal payments through maturity and include a balloon principal payment upon maturity.

 

Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
Recent Accounting Pronouncements
3 Months Ended
Mar. 31, 2016
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]  
Recent Accounting Pronouncements

(6) Recent Accounting Pronouncements

 

In March, 2016, the FASB issued ASU 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting, which requires an investor to initially apply the equity method of accounting from the date it qualified for that method.  The ASU eliminates the previous requirement to retroactively adjust the investment and record a cumulative catch up for the periods that the investment had been held, but did not qualify for the equity method of accounting.  The amendments are effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted.  We are currently in the process of evaluating the impact of adoption of this ASU on our consolidated financial statements.

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASU 2016-02 supersedes the previous leases standard, Leases (Topic 840). The standard is effective on January 1, 2019, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of ASU 2016-02 will have on our financial position or results of operations.

 

In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs, an update to the accounting standard relating to the presentation of debt issuance costs. Under the new guidance, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability. In the event that there is not an associated debt liability recorded in the consolidated financial statements, the debt issuance costs will continue to be recorded on the consolidated balance sheet as an asset until the debt liability is recorded.  The new standard became effective for the Trust on January 1, 2016. The adoption of this guidance did not have a material impact on our consolidated financial position or results of operations as the update only related to changes in financial statement presentation.  

 

In February 2015, the FASB issued ASU No. 2015-02, Consolidation – Amendments to the Consolidation Analysis, which amends the current consolidation guidance affecting both the variable interest entity (“VIE”) and voting interest entity (“VOE”) consolidation models. The standard does not add or remove any of the characteristics in determining if an entity is a VIE or VOE, but rather enhances the way the Company assesses some of these characteristics. The new standard became effective for the Trust on January 1, 2016 and did not have a material impact on our consolidated financial position or results of operations as none of its existing consolidation conclusions were changed.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
Debt and Financial Instruments
3 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Debt and Financial Instruments

(7) Debt and Financial Instruments

Debt:

 

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $185 million revolving credit facility, the level of borrowings pursuant to non-course mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our at-the-market equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit facility borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On March 27, 2015, we entered into a new $185 million revolving credit agreement (“Credit Agreement”). The Credit Agreement, which will mature in March, 2019, replaced our previous revolving credit facility which was scheduled to mature in July, 2015. The Credit Agreement includes a $50 million sub limit for letters of credit and a $20 million sub limit for swingline/short-term loans. The Credit Agreement also provides a one-time option to extend the maturity date for an additional one year period, and an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement. Borrowings under the new facility are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the new facility are secured by first priority security interests in and liens on all equity interests in the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.50% to 2.00% or at the Base Rate plus an applicable margin ranging from 0.50% to 1.00%. The Credit Agreement defines “Base Rate” as the greatest of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%. A commitment fee of 0.20% to 0.40% (depending on our total leverage ratio) will be charged on the average unused portion of the revolving credit commitments. The margins over LIBOR, Base Rate and the commitment fee are based upon our ratio of debt to total capital. At March 31, 2016, the applicable margin over the LIBOR rate was 1.625%, the margin over the Base Rate was 0.625%, and the commitment fee was 0.25%.

At March 31, 2016, we had $159.7 million of outstanding borrowings and $3.0 million of letters of credit outstanding against our revolving credit agreement. We had $22.3 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2016. At December 31, 2015, we had $142.2 million of outstanding borrowings and $3.5 million of letters of credit outstanding against our revolving credit agreement. We had $39.3 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of December 31, 2015. There are no compensating balance requirements.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2016. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

 

March 31,

2016

 

Tangible net worth

 

$

125,000

 

 

$

171,326

 

Total leverage

 

< 60%

 

 

 

46.6

%

Secured leverage

 

< 30%

 

 

 

19.4

%

Unencumbered leverage

 

< 60%

 

 

 

46.2

%

Fixed charge coverage

 

> 1.50x

 

 

3.5x

 

 

As indicated on the following table, we have fourteen mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2016, with a combined outstanding balance of $109.5 million, excluding net debt premium of $242,000 and net of net financing fees of $376,000 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands)(a)

 

 

Interest

Rate

 

 

Maturity

Date

Summerlin Hospital Medical Office Building III

   floating rate mortgage loan (b.)

 

$

10,616

 

 

 

3.69

%

 

December, 2016

Peace Health fixed rate mortgage loan (b.)

 

 

20,671

 

 

 

5.64

%

 

April, 2017

Auburn Medical II floating rate mortgage loan (b.)

 

 

6,897

 

 

 

3.19

%

 

April, 2017

Medical Center of Western Connecticut fixed rate

   mortgage loan

 

 

4,631

 

 

 

6.00

%

 

June, 2017

Summerlin Hospital Medical Office Building II fixed

   rate mortgage loan

 

 

11,339

 

 

 

5.50

%

 

October, 2017

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

6,312

 

 

 

5.88

%

 

December, 2017

Centennial Hills Medical Office Building floating rate

   mortgage loan

 

 

10,266

 

 

 

3.69

%

 

January, 2018

Sparks Medical Building/Vista Medical Terrace

   floating rate mortgage loan

 

 

4,320

 

 

 

3.69

%

 

February, 2018

Rosenberg Children’s Medical Plaza fixed rate

   mortgage loan

 

 

8,275

 

 

 

4.85

%

 

May, 2018

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

 

2,793

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

6,384

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,453

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

5,179

 

 

 

3.62

%

 

January, 2023

Tuscan Professional Building fixed rate mortgage loan

 

 

5,330

 

 

 

5.56

%

 

June, 2025

Total

 

$

109,466

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.

(b.)

This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our revolving credit facility.

The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages have a combined fair value of approximately $112 million as of March 31, 2016. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

At December 31, 2015, we had fourteen mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these fourteen mortgages was $110.3 million (excluding net debt premium of $298,000 and net of net financing fees of $398,000), and had a combined fair value of approximately $112.4 million.

Financial Instruments:

During the third quarter of 2013, we entered into an interest rate cap on a total notional amount of $10 million whereby we paid a premium of $136,000. During the first quarter of 2014, we entered into two additional interest rate cap agreements on a total notional amount of $20 million whereby we paid premiums of $134,500. In exchange for the premium payments, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap. From inception through March 31, 2016, no payments have been made to us by the counterparties pursuant to the terms of these caps which expire in January, 2017.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
Segment Reporting
3 Months Ended
Mar. 31, 2016
Segment Reporting [Abstract]  
Segment Reporting

(8) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2016
Related Party Transactions [Abstract]  
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2016

 

 

15

 

(a)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2016

 

 

15

 

(b)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2016

 

 

15

 

(b)

 

(a)

UHS has three 5-year renewal options at existing lease rates (through 2031).

(b)

UHS has one 5-year renewal option at existing lease rates (through 2021) and two 5-year renewal options at fair market value lease rates (2022 through 2031).

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
Acquisitions, Dispositions and New Construction (Tables)
3 Months Ended
Mar. 31, 2016
Business Combinations [Abstract]  
Allocation of Purchase Price to Assets Acquired and Liabilities Assumed

 

The aggregate purchase price for this MOB was allocated to the assets acquired and liabilities assumed consisting of tangible property and identified intangible assets, based on the fair value estimated at acquisition as detailed in the table below. Substantially all of the intangible assets include the value of the in-place leases at the MOB at the time of acquisition which will be amortized over the average remaining lease term of approximately 6.2 years at the time of acquisition.

 

 

 

Land

$2,328

Buildings and improvements

6,523

Intangible assets

1,209

Deposit

(150)

 

 

Net cash paid

$9,910

 

 

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summarized Financial Information of Equity Affiliates (Tables)
3 Months Ended
Mar. 31, 2016
Equity Method Investments And Joint Ventures [Abstract]  
Limited Liability Companies Accounted for Under Equity Method

The following property table represents the five LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of March 31, 2016:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)

 

 

74

%

 

Mid Coast Hospital MOB

Arlington Medical Properties (b.)

 

 

85

%

 

Saint Mary’s Professional Office Building

Grayson Properties (c.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (d.)

 

 

95

%

 

Forney Medical Plaza II

 

(a.)

This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of March 31, 2016.

(b.)

We have funded $5.2 million in equity as of March 31, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date.  The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%.

(c.)

We have funded $2.8 million in equity as of March 31, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.6 million outstanding as of March 31, 2016.

(d.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.0 million has been funded as of March 31, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.4 million outstanding as of March 31, 2016.

Condensed Combined Statements of Income (Unaudited) for Limited Liability Companies Accounted for Under Equity Method

Below are the condensed combined statements of income (unaudited) for the LLCs accounted for under the equity method at March 31, 2016 and 2015.  

 

 

 

Three Months Ended

March 31,

 

 

 

 

2016

 

 

2015

 

 

 

 

(amounts in thousands)

Revenues

 

$

3,736

 

 

$

3,585

 

 

Operating expenses

 

 

1,353

 

 

 

1,337

 

 

Depreciation and amortization

 

 

613

 

 

 

580

 

 

Interest, net

 

 

657

 

 

 

619

 

 

Net income

 

$

1,113

 

 

$

1,049

 

 

Our share of net income (a.)

 

$

1,059

 

 

$

592

 

 

 

(a.)

Our share of net income for the three months ended March 31, 2016 includes interest income earned by us on an advance made to Arlington Medical Properties, LLC of approximately $296,000. There were no advances outstanding during the first three months of 2015, therefore there was no interest income earned by us for the three months ended March 31, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.

 

Condensed Combined Balance Sheets (Unaudited) for LLCs Accounted for Under Equity Method

Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs in which we hold noncontrolling ownership interests and that were accounted for under the equity method as of March 31, 2016 and December 31, 2015:

 

 

 

March 31,

2016

 

 

December 31,

2015

 

 

 

(amounts in thousands)

 

Net property, including CIP

 

$

61,838

 

 

$

61,668

 

Other assets

 

 

5,415

 

 

 

5,264

 

Total assets

 

$

67,253

 

 

$

66,932

 

 

 

 

 

 

 

 

 

 

Liabilities

 

$

2,657

 

 

$

2,538

 

Mortgage notes payable, non-recourse to us

 

 

28,763

 

 

 

28,895

 

Advances payable to us

 

 

22,280

 

 

 

22,489

 

Equity

 

 

13,553

 

 

 

13,010

 

Total liabilities and equity

 

$

67,253

 

 

$

66,932

 

 

 

 

 

 

 

 

 

 

Our share of equity in  and advances to LLCs reflected as:

 

 

 

 

 

 

 

 

   Investments in LLCs (a.)

 

$

14,555

 

 

$

9,108

 

   Advances to LLCs

 

 

22,280

 

 

 

22,489

 

Subtotal-Investments in and advances to LLCs before

 

 

 

 

 

 

 

 

   amounts included in accrued expenses and other liabilities

 

 

36,835

 

 

 

31,597

 

   Amounts included in accrued expenses and other liabilities

 

 

(1,311

)

 

 

(1,105

)

Our share of equity in and advances to LLCs, net

 

$

35,524

 

 

$

30,492

 

 

 

(a.)

As mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.

Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's Accounted Under Equity Method

As of March 31, 2016, and December 31, 2015, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

3/31/2016

 

 

12/31/2015

 

 

Maturity Date

FTX MOB Phase II

 

$

5,396

 

 

$

5,427

 

 

August, 2017

Grayson Properties

 

 

14,612

 

 

 

14,670

 

 

September, 2021

Brunswick Associates

 

 

8,755

 

 

 

8,798

 

 

December, 2024

 

 

$

28,763

 

 

$

28,895

 

 

 

 

(a.)

All mortgage loans, other than construction loans, require monthly principal payments through maturity and include a balloon principal payment upon maturity.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
Debt and Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

 

March 31,

2016

 

Tangible net worth

 

$

125,000

 

 

$

171,326

 

Total leverage

 

< 60%

 

 

 

46.6

%

Secured leverage

 

< 30%

 

 

 

19.4

%

Unencumbered leverage

 

< 60%

 

 

 

46.2

%

Fixed charge coverage

 

> 1.50x

 

 

3.5x

 

 

Outstanding Mortgages, Excluding Net Debt Premium

 

Facility Name

 

Outstanding

Balance

(in thousands)(a)

 

 

Interest

Rate

 

 

Maturity

Date

Summerlin Hospital Medical Office Building III

   floating rate mortgage loan (b.)

 

$

10,616

 

 

 

3.69

%

 

December, 2016

Peace Health fixed rate mortgage loan (b.)

 

 

20,671

 

 

 

5.64

%

 

April, 2017

Auburn Medical II floating rate mortgage loan (b.)

 

 

6,897

 

 

 

3.19

%

 

April, 2017

Medical Center of Western Connecticut fixed rate

   mortgage loan

 

 

4,631

 

 

 

6.00

%

 

June, 2017

Summerlin Hospital Medical Office Building II fixed

   rate mortgage loan

 

 

11,339

 

 

 

5.50

%

 

October, 2017

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

6,312

 

 

 

5.88

%

 

December, 2017

Centennial Hills Medical Office Building floating rate

   mortgage loan

 

 

10,266

 

 

 

3.69

%

 

January, 2018

Sparks Medical Building/Vista Medical Terrace

   floating rate mortgage loan

 

 

4,320

 

 

 

3.69

%

 

February, 2018

Rosenberg Children’s Medical Plaza fixed rate

   mortgage loan

 

 

8,275

 

 

 

4.85

%

 

May, 2018

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

 

2,793

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

6,384

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,453

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

5,179

 

 

 

3.62

%

 

January, 2023

Tuscan Professional Building fixed rate mortgage loan

 

 

5,330

 

 

 

5.56

%

 

June, 2025

Total

 

$

109,466

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.

(b.)

This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our revolving credit facility.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.4.0.3
General - Additional Information (Detail)
Mar. 31, 2016
Property
5 Unconsolidated Limited Liability Companies | Minimum  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Non-controlling equity interest, ownership percentage 33.00%
5 Unconsolidated Limited Liability Companies | Maximum  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Non-controlling equity interest, ownership percentage 95.00%
Medical office buildings | Limited Liability Companies  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Number of real estate investments 5
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.4.0.3
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail)
3 Months Ended
Mar. 31, 2016
USD ($)
Property
Time
Mar. 31, 2015
USD ($)
Dec. 31, 2015
Related Party Transaction [Line Items]      
Maximum amount of investment for development and construction $ 21,100,000    
Advisory fee $ 767,000 $ 666,000  
Minimum | 5 Unconsolidated Limited Liability Companies      
Related Party Transaction [Line Items]      
Non-controlling equity interest, ownership percentage 33.00%    
Maximum | 5 Unconsolidated Limited Liability Companies      
Related Party Transaction [Line Items]      
Non-controlling equity interest, ownership percentage 95.00%    
Universal Health Services, Inc      
Related Party Transaction [Line Items]      
Number of term renewal options | Time 6    
Additional renewal terms 5 years    
Number of medical office buildings and free standing emergency departments | Property 16    
Option to renew lease, notice period prior to termination date of current term 90 days    
Period to purchase respective leased facilities at same price after lease terms 180 days    
Renewal period of respective leased facilities at same price after lease terms 180 days    
Percentage ownership of outstanding shares 5.90%   5.90%
Number of renewal options at existing lease rates | Time 3    
Lease term scheduled end date 2016-12    
Universal Health Services, Inc | Customer Concentration Risk | Revenues      
Related Party Transaction [Line Items]      
Percentage of revenues generated from leases 25.00% 25.00%  
Universal Health Services, Inc | Customer Concentration Risk | Combined consolidated and unconsolidated revenue      
Related Party Transaction [Line Items]      
Percentage of revenues generated from leases 20.00% 20.00%  
Universal Health Services, Inc | Minimum      
Related Party Transaction [Line Items]      
Initial lease terms 13 years    
Universal Health Services, Inc | Maximum      
Related Party Transaction [Line Items]      
Initial lease terms 15 years    
Universal Health Services of Delaware Inc      
Related Party Transaction [Line Items]      
Annual incentive fee to Advisor as percentage of cash available for distribution 20.00%    
Incentive fees $ 0 $ 0  
Advisory fee 767,000 666,000  
Average invested real estate assets $ 438,000,000 $ 381,000,000  
Universal Health Services of Delaware Inc | Minimum      
Related Party Transaction [Line Items]      
Percentage of equity to be exceeded for incentive distribution 15.00%    
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail)
3 Months Ended
Mar. 31, 2016
USD ($)
McAllen Medical Center  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 5,485,000
End of Lease Term 2016-12
Renewal Term (years) 15 years [1]
Wellington Regional Medical Center  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 3,030,000
End of Lease Term 2016-12
Renewal Term (years) 15 years [2]
Southwest Healthcare System, Inland Valley Campus  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 2,648,000
End of Lease Term 2016-12
Renewal Term (years) 15 years [2]
[1] UHS has three 5-year renewal options at existing lease rates (through 2031).
[2] UHS has one 5-year renewal option at existing lease rates (through 2021) and two 5-year renewal options at fair market value lease rates (2022 through 2031).
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) - Universal Health Services, Inc
3 Months Ended
Mar. 31, 2016
Time
RenewalOption
Operating Leased Assets [Line Items]  
Number of renewal options at existing lease rates | Time 3
McAllen Medical Center  
Operating Leased Assets [Line Items]  
Number of renewal options at existing lease rates | Time 3
Renewal options term at existing lease rates 5 years
Renewal options at existing lease rates expiration year 2031
Wellington Regional Medical Center And Southwest Healthcare System  
Operating Leased Assets [Line Items]  
Number of renewal options at existing lease rates | RenewalOption 1
Renewal options term at existing lease rates 5 years
Renewal options at existing lease rates expiration year 2021
Number of renewal options at fair market value lease rates | RenewalOption 2
Renewal options term at fair market value lease rates 5 years
Wellington Regional Medical Center And Southwest Healthcare System | Minimum  
Operating Leased Assets [Line Items]  
Renewal options at fair market value lease rates expiration year 2022
Wellington Regional Medical Center And Southwest Healthcare System | Maximum  
Operating Leased Assets [Line Items]  
Renewal options at fair market value lease rates expiration year 2031
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
Dividends and Equity Issuance Program - Additional Information (Detail) - USD ($)
3 Months Ended 30 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2016
Dividends and Equity Issuance [Line Items]      
Dividends declared and paid $ 8,596,000 $ 8,446,000  
Declared and paid dividends, per share $ 0.645 $ 0.635  
Securities, aggregate sales price $ 23,300,000   $ 23,300,000
At-The-Market (ATM) Equity Issuance Program      
Dividends and Equity Issuance [Line Items]      
Share issued 0   580,900
Average sale price per share     $ 45.97
Net cash proceeds from stock issued     $ 25,600,000
Payment of stock issuance cost   $ 1,100,000 1,100,000
Payments for stock issuance     667,000
At-The-Market (ATM) Equity Issuance Program | Other Expense      
Dividends and Equity Issuance [Line Items]      
Payments for stock issuance     $ 391,000
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.4.0.3
Acquisitions, Dispositions and New Construction - Additional Information (Detail)
1 Months Ended 2 Months Ended 3 Months Ended
Mar. 31, 2016
USD ($)
ft²
Time
Feb. 28, 2015
USD ($)
ft²
Time
Building
Feb. 28, 2015
USD ($)
ft²
Property
Time
Mar. 31, 2016
USD ($)
ft²
Time
Mar. 31, 2015
USD ($)
Business Acquisitions And Dispositions [Line Items]          
Net rentable area | ft²   16,000 16,000    
Total purchase price   $ 4,100,000 $ 4,100,000    
Maximum amount of investment for development and construction $ 21,100,000     $ 21,100,000  
Cash received for property exchange transaction       $ 0 $ 0
Number of Buildings purchased | Building   2      
Mission and Weslaco Freestanding Emergency Departments          
Business Acquisitions And Dispositions [Line Items]          
Total purchase price   $ 12,800,000 $ 12,800,000    
Number of real properties purchased | Property     2    
Area of acquired building | ft²   13,600 13,600    
Lease agreement period     10 years    
Universal Health Services, Inc          
Business Acquisitions And Dispositions [Line Items]          
Number of term renewal options | Time 6     6  
Additional renewal terms       5 years  
Universal Health Services, Inc | Mission and Weslaco Freestanding Emergency Departments          
Business Acquisitions And Dispositions [Line Items]          
Number of term renewal options | Time   6 6    
Additional renewal terms     5 years    
Madison Professional Office Building          
Business Acquisitions And Dispositions [Line Items]          
Net rentable area | ft² 30,100     30,100  
Renewal Term (years) 6 years 2 months 12 days        
Total purchase price $ 10,100,000     $ 10,100,000  
Medical office buildings          
Business Acquisitions And Dispositions [Line Items]          
Lease term       6 years 2 months 12 days  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Detail) - 2016 Acquisitions
$ in Thousands
Mar. 31, 2016
USD ($)
Business Acquisition [Line Items]  
Land $ 2,328
Buildings and improvements 6,523
Intangible assets 1,209
Deposit (150)
Net cash paid $ 9,910
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summarized Financial Information of Equity Affiliates - Additional Information (Detail)
3 Months Ended
Mar. 31, 2016
Property
Limited Liability Companies | Medical office buildings  
Schedule Of Equity Method Investments [Line Items]  
Number of real estate investments 5
Minimum  
Schedule Of Equity Method Investments [Line Items]  
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member 60 days
Maximum  
Schedule Of Equity Method Investments [Line Items]  
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member 90 days
5 Unconsolidated Limited Liability Companies / Limited Partner | Minimum  
Schedule Of Equity Method Investments [Line Items]  
Non-controlling equity interest, ownership percentage 33.00%
5 Unconsolidated Limited Liability Companies / Limited Partner | Maximum  
Schedule Of Equity Method Investments [Line Items]  
Non-controlling equity interest, ownership percentage 95.00%
Arlington Medical Properties  
Schedule Of Equity Method Investments [Line Items]  
Non-controlling equity interest, ownership percentage 85.00%
Percentage of minority ownership purchased from third-party members 10.00%
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
Limited Liability Companies Accounted for Under Equity Method (Detail)
3 Months Ended
Mar. 31, 2016
Arlington Medical Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 85.00%
Equity Method Investments | Suburban Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 33.00%
Property Owned by LLC St. Matthews Medical Plaza II
Equity Method Investments | Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Ownership 74.00% [1]
Property Owned by LLC Mid Coast Hospital MOB [1]
Equity Method Investments | Arlington Medical Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 85.00% [2]
Property Owned by LLC Saint Mary’s Professional Office Building [2]
Equity Method Investments | Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [3]
Property Owned by LLC Texoma Medical Plaza [3]
Equity Method Investments | FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [4]
Property Owned by LLC Forney Medical Plaza II [4]
[1] This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of March 31, 2016.
[2] We have funded $5.2 million in equity as of March 31, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date. The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%.
[3] We have funded $2.8 million in equity as of March 31, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.6 million outstanding as of March 31, 2016.
[4] We have committed to invest up to $2.5 million in equity and debt financing, of which $2.0 million has been funded as of March 31, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.4 million outstanding as of March 31, 2016.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.4.0.3
Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail)
3 Months Ended
Mar. 31, 2016
USD ($)
Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan $ 8,700,000
Arlington Medical Properties  
Schedule Of Equity Method Investments [Line Items]  
Committed investment in equity and debt financing, funded 5,200,000
Commitment to investment 623,000
Proceeds from Lines of Credit $ 22,800,000
Percentage of minority ownership purchased from third-party members 10.00%
Business acquisition additional consideration $ 4,800,000
Cash payment made purchased addition of ownership interest 85.00%
Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan $ 14,600,000
Committed investment in equity and debt financing, funded 2,800,000
Commitment to investment 100,000
FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan 5,400,000
Committed investment in equity and debt financing, funded 2,000,000
Commitment to investment $ 2,500,000
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Equity Method Investments And Joint Ventures [Abstract]    
Revenues $ 3,736 $ 3,585
Operating expenses 1,353 1,337
Depreciation and amortization 613 580
Interest, net 657 619
Net income 1,113 1,049
Our share of net income [1] $ 1,059 $ 592
[1] Our share of net income for the three months ended March 31, 2016 includes interest income earned by us on an advance made to Arlington Medical Properties, LLC of approximately $296,000. There were no advances outstanding during the first three months of 2015, therefore there was no interest income earned by us for the three months ended March 31, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) - Arlington Medical Properties - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Schedule Of Equity Method Investments [Line Items]      
Interest income earned on various advances made to LLCs $ 296,000 $ 0  
Percentage of minority ownership purchased from third-party members 10.00%    
Cash payment made purchased addition of ownership interest 85.00%   75.00%
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Equity Method Investments And Joint Ventures [Abstract]    
Net property, including CIP $ 61,838 $ 61,668
Other assets 5,415 5,264
Total assets 67,253 66,932
Liabilities 2,657 2,538
Mortgage notes payable, non-recourse to us 28,763 28,895
Advances payable to us 22,280 22,489
Equity 13,553 13,010
Total liabilities and equity 67,253 66,932
Our share of equity in and advances to LLCs reflected as:    
Investments in LLCs [1] 14,555 9,108
Advances to LLCs 22,280 22,489
Subtotal-Investments in and advances to LLCs before amounts included in accrued expenses and other liabilities 36,835 31,597
Amounts included in accrued expenses and other liabilities (1,311) (1,105)
Our share of equity in and advances to LLCs, net $ 35,524 $ 30,492
[1] As mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% in 2015.
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) - Arlington Medical Properties
3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Schedule Of Equity Method Investments [Line Items]    
Percentage of minority ownership purchased from third-party members 10.00%  
Cash payment made purchased addition of ownership interest 85.00% 75.00%
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.4.0.3
Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance $ 28,763 $ 28,895
Equity Method Investments    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] 28,763 28,895
Equity Method Investments | FTX MOB Phase II    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 5,396 5,427
Maturity Date 2017-08  
Equity Method Investments | Grayson Properties    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 14,612 14,670
Maturity Date 2021-09  
Equity Method Investments | Brunswick Associates    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 8,755 $ 8,798
Maturity Date 2024-12  
[1] All mortgage loans, other than construction loans, require monthly principal payments through maturity and include a balloon principal payment upon maturity.
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.4.0.3
Debt and Financial Instruments - Additional Information (Detail)
3 Months Ended
Mar. 31, 2016
USD ($)
MortgageLoan
Mar. 27, 2015
USD ($)
Option
Mar. 31, 2016
USD ($)
MortgageLoan
Mar. 31, 2014
USD ($)
Derivative
Sep. 30, 2013
USD ($)
Derivative
Dec. 31, 2015
USD ($)
MortgageLoan
Debt Instrument [Line Items]            
Mortgage loan fair value $ 112,000,000   $ 112,000,000     $ 112,400,000
Number of non-recourse mortgages | MortgageLoan 14   14     14
Balance of Non Recourse Mortgages $ 109,466,000 [1]   $ 109,466,000 [1]     $ 110,300,000
Mortgage and other notes payable, non-recourse to us, debt premium 242,000,000   242,000,000     298,000
Financing fees net 376,000,000   376,000,000     398,000
Outstanding borrowings under revolving credit agreement 159,650,000   159,650,000     142,150,000
Outstanding borrowings under letter of credit 3,000,000   3,000,000     3,500,000
Available borrowing capacity $ 22,300,000   $ 22,300,000     $ 39,300,000
Interest Rate Cap            
Debt Instrument [Line Items]            
Number of interest rate cap agreements | Derivative       2 1  
Notional amount       $ 20,000,000 $ 10,000,000  
Premium paid       $ 134,500 $ 136,000  
Expiration date of interest rate cap       Jan. 31, 2017 Jan. 31, 2017  
LIBOR | Interest Rate Cap            
Debt Instrument [Line Items]            
Derivative instruments, LIBOR rate       1.50% 1.50%  
New Revolving Credit Facility Agreement            
Debt Instrument [Line Items]            
Outstanding borrowing   $ 185,000,000        
Unsecured revolving credit agreement terminated date   2019-03        
Number of additional one year extension options | Option   1        
Proceeds from Lines of Credit   $ 50,000,000        
Credit facility, Interest Rate Terms     One, two, three, or six month LIBOR plus an applicable margin ranging from 1.50% to 2.00% or at the Base Rate plus an applicable margin ranging from 0.50% to 1.00%.      
Base rate description     The greatest of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.      
Fee payable on unused portion of commitment 0.25%          
New Revolving Credit Facility Agreement | LIBOR            
Debt Instrument [Line Items]            
Margin points added to the reference rate 1.625%          
New Revolving Credit Facility Agreement | Base Rate            
Debt Instrument [Line Items]            
Margin points added to the reference rate 0.625%          
New Revolving Credit Facility Agreement | Swingline/Short-Term Loans            
Debt Instrument [Line Items]            
Outstanding borrowing   20,000,000        
New Revolving Credit Facility Agreement | Letters of Credit            
Debt Instrument [Line Items]            
Outstanding borrowing   $ 50,000,000        
Previous Revolving Credit Facility            
Debt Instrument [Line Items]            
Unsecured revolving credit agreement terminated date   2015-07        
Minimum | New Revolving Credit Facility Agreement            
Debt Instrument [Line Items]            
Fee payable on unused portion of commitment   0.20%        
Minimum | New Revolving Credit Facility Agreement | LIBOR            
Debt Instrument [Line Items]            
Margin points added to the reference rate   1.50%        
Margin points added to the base rate   1.00%        
Minimum | New Revolving Credit Facility Agreement | Base Rate            
Debt Instrument [Line Items]            
Margin points added to the reference rate   0.50%        
Minimum | New Revolving Credit Facility Agreement | Federal Funds Effective Rate            
Debt Instrument [Line Items]            
Margin points added to the base rate   0.50%        
Maximum | New Revolving Credit Facility Agreement            
Debt Instrument [Line Items]            
Fee payable on unused portion of commitment   0.40%        
Maximum | New Revolving Credit Facility Agreement | LIBOR            
Debt Instrument [Line Items]            
Margin points added to the reference rate   2.00%        
Maximum | New Revolving Credit Facility Agreement | Base Rate            
Debt Instrument [Line Items]            
Margin points added to the reference rate   1.00%        
[1] All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail)
$ in Thousands
3 Months Ended
Mar. 31, 2016
USD ($)
Debt Instrument [Line Items]  
Covenant, Tangible net worth $ 125,000
Tangible net worth $ 171,326
Total leverage 46.60%
Secured leverage 19.40%
Unencumbered leverage 46.20%
Fixed charge coverage 3.50%
Maximum  
Debt Instrument [Line Items]  
Covenant, Total leverage 60.00%
Covenant, Secured leverage 30.00%
Covenant, Unencumbered leverage 60.00%
Minimum  
Debt Instrument [Line Items]  
Covenant, Fixed charge coverage 1.50%
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Debt Instrument [Line Items]    
Outstanding Balance $ 109,466 [1] $ 110,300
Summerlin Hospital Medical Office Building III floating rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1],[2] $ 10,616  
Debt Instrument Interest Rate Stated Percentage [2] 3.69%  
Maturity Date [2] 2016-12  
Peace Health fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1],[2] $ 20,671  
Debt Instrument Interest Rate Stated Percentage [2] 5.64%  
Maturity Date [2] 2017-04  
Auburn Medical II floating rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1],[2] $ 6,897  
Debt Instrument Interest Rate Stated Percentage [2] 3.19%  
Maturity Date [2] 2017-04  
Medical Center of Western Connecticut fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 4,631  
Debt Instrument Interest Rate Stated Percentage 6.00%  
Maturity Date 2017-06  
Summerlin Hospital Medical Office Building II fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 11,339  
Debt Instrument Interest Rate Stated Percentage 5.50%  
Maturity Date 2017-10  
Phoenix Children's East Valley Care Center Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 6,312  
Debt Instrument Interest Rate Stated Percentage 5.88%  
Maturity Date 2017-12  
Centennial Hills Medical Office Building floating rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 10,266  
Debt Instrument Interest Rate Stated Percentage 3.69%  
Maturity Date 2018-01  
Sparks Medical Building/Vista Medical Terrace Floating Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 4,320  
Debt Instrument Interest Rate Stated Percentage 3.69%  
Maturity Date 2018-02  
Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 8,275  
Debt Instrument Interest Rate Stated Percentage 4.85%  
Maturity Date 2018-05  
Vibra Hospital-Corpus Christi fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 2,793  
Debt Instrument Interest Rate Stated Percentage 6.50%  
Maturity Date 2019-07  
700 Shadow Lane and Goldring MOBs fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 6,384  
Debt Instrument Interest Rate Stated Percentage 4.54%  
Maturity Date 2022-06  
BRB Medical Office Building fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 6,453  
Debt Instrument Interest Rate Stated Percentage 4.27%  
Maturity Date 2022-12  
Desert Valley Medical Center Floating Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 5,179  
Debt Instrument Interest Rate Stated Percentage 3.62%  
Maturity Date 2023-01  
Tuscan Professional Building fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 5,330  
Debt Instrument Interest Rate Stated Percentage 5.56%  
Maturity Date 2025-06  
[1] All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.
[2] This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our revolving credit facility.
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.4.0.3
Segment Reporting - Additional Information (Detail)
3 Months Ended
Mar. 31, 2016
Segment
Segment Reporting [Abstract]  
Number of reportable segments 1
EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 129 217 1 true 55 0 false 13 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.uhrit.com/20160331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Statements of Income Sheet http://www.uhrit.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.uhrit.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.uhrit.com/20160331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.uhrit.com/20160331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statement of Cash Flows Sheet http://www.uhrit.com/20160331/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows Condensed Consolidated Statement of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - General Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureGeneral General Notes 7 false false R8.htm 100070 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Notes 8 false false R9.htm 100080 - Disclosure - Dividends and Equity Issuance Program Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram Dividends and Equity Issuance Program Notes 9 false false R10.htm 100090 - Disclosure - Acquisitions, Dispositions and New Construction Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureAcquisitionsDispositionsAndNewConstruction Acquisitions, Dispositions and New Construction Notes 10 false false R11.htm 100100 - Disclosure - Summarized Financial Information of Equity Affiliates Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates Summarized Financial Information of Equity Affiliates Notes 11 false false R12.htm 100110 - Disclosure - Recent Accounting Pronouncements Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 12 false false R13.htm 100120 - Disclosure - Debt and Financial Instruments Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureDebtAndFinancialInstruments Debt and Financial Instruments Notes 13 false false R14.htm 100130 - Disclosure - Segment Reporting Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureSegmentReporting Segment Reporting Notes 14 false false R15.htm 100140 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Tables http://www.uhrit.com/20160331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions 15 false false R16.htm 100150 - Disclosure - Acquisitions, Dispositions and New Construction (Tables) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureAcquisitionsDispositionsAndNewConstructionTables Acquisitions, Dispositions and New Construction (Tables) Tables http://www.uhrit.com/20160331/taxonomy/role/DisclosureAcquisitionsDispositionsAndNewConstruction 16 false false R17.htm 100160 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables Summarized Financial Information of Equity Affiliates (Tables) Tables http://www.uhrit.com/20160331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates 17 false false R18.htm 100170 - Disclosure - Debt and Financial Instruments (Tables) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables Debt and Financial Instruments (Tables) Tables http://www.uhrit.com/20160331/taxonomy/role/DisclosureDebtAndFinancialInstruments 18 false false R19.htm 100180 - Disclosure - General - Additional Information (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail General - Additional Information (Detail) Details 19 false false R20.htm 100190 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Details http://www.uhrit.com/20160331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables 20 false false R21.htm 100200 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Details 21 false false R22.htm 100210 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Details 22 false false R23.htm 100220 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail Dividends and Equity Issuance Program - Additional Information (Detail) Details 23 false false R24.htm 100230 - Disclosure - Acquisitions, Dispositions and New Construction - Additional Information (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureAcquisitionsDispositionsAndNewConstructionAdditionalInformationDetail Acquisitions, Dispositions and New Construction - Additional Information (Detail) Details 24 false false R25.htm 100240 - Disclosure - Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetail Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Detail) Details 25 false false R26.htm 100250 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Details 26 false false R27.htm 100260 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail Limited Liability Companies Accounted for Under Equity Method (Detail) Details 27 false false R28.htm 100270 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Details 28 false false R29.htm 100280 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLimitedLiabilitiesAccountedForUnderEquityMethodDetail Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) Details 29 false false R30.htm 100290 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLimitedLiabilitiesAccountedForUnderEquityMethodParentheticalDetail Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) Details 30 false false R31.htm 100300 - Disclosure - Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsOfLimitedLiabilitiesAccountedForUnderEquityMethodDetail Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) Details 31 false false R32.htm 100310 - Disclosure - Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsOfLimitedLiabilitiesAccountedForUnderEquityMethodParentheticalDetail Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) Details 32 false false R33.htm 100320 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) Notes http://www.uhrit.com/20160331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcsAccountedUnderEquityMethodDetail Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) Details 33 false false R34.htm 100330 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail Debt and Financial Instruments - Additional Information (Detail) Details 34 false false R35.htm 100340 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Details 35 false false R36.htm 100350 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Details 36 false false R37.htm 100360 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://www.uhrit.com/20160331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail Segment Reporting - Additional Information (Detail) Details 37 false false All Reports Book All Reports uht-20160331.xml uht-20160331.xsd uht-20160331_cal.xml uht-20160331_def.xml uht-20160331_lab.xml uht-20160331_pre.xml true true ZIP 55 0001564590-16-018296-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-16-018296-xbrl.zip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